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 Conflicting results between benchtop experiments, animal models, and clinical 
trials have posed a significant challenge in translational medical research, motivating the 
development of technologies with which to assess and screen experimental therapeutics. 
Among these new technologies are microfluidic platforms that allow for the synthesis of 
nanoparticles and the tuning of microenvironments to replicate the ideal physiological 
conditions to study living responses in vitro. The advantages of using microfluidic 
technologies in order to accomplish these feats are attributed to volumetrically minimal 
usage of expensive reagents while also having the capacity to be run continuously for 
high-throughput and large-scale applications. Some of the challenges still associated to 
the general adoption of microfluidic technologies are those typically found in the early 
stages of new technological advancements: (1) a lack of standardization in work flow and 
platform design, and (2) a limited accessibility to specialized equipment. This thesis 
focuses on contributing to the standardization of the microfluidic workflow through 
exploring both platform designs for the synthesis and screening of nanoparticles, and 
exploring key translational questions with experiments that are uniquely enabled with 
microfluidics. The microfluidic platforms that are presented in this work are a mixer for 
nanoparticle synthesis and a monitor for the permeability of a cellular monolayer. These 
platforms were implemented in experiments studying the functionality of high-density 
lipoprotein mimetic nanoparticles and their interactions with endothelial cells within the 
context of cardiovascular disease. We report how the functionality of the high-density 
lipoprotein mimetic nanoparticles is affected by its protein composition, and how its 
interactions with the endothelial monolayer are modulated depending on the oscillatory 
flow stimulated inflammatory condition of the endothelial cells.
 1 
CHAPTER 1. INTRODUCTION 
1.1 BACKGROUND 
 
Cardiovascular disease (CVD) impacts one of the largest groups of individuals 
throughout the world [1]. One of the most common manifestations of CVD is through the 
formation of atherosclerotic plaques that lead to vascular occlusion and stiffening [2]. 
Initiation of atherosclerosis is preceded by chronic inflammation of the endothelium that 
largely occurs in areas with disturbed flow and high cholesterol levels in the blood [3, 4]. 
These areas with disturbed, or oscillatory, flow are largely localized to specific regions of 
vasculature: (1) carotid arteries, (2) coronary arteries, (3) abdominal aorta, and (4) ilio-
femoral arteries (Fig. 1.1) [5]. Of these regions, the carotid arteries and ilio-femoral arteries 
have the highest prevalence of atherosclerotic plaques due to their unique geometries that 
enable the generation of disturbed flow profiles. 
 
Figure 1.1. Prevalence of localized atherosclerosis in vasculature. 
Atherosclerosis localization is most dominant in the regions with the most disturbed flow profiles: 
the carotid arteries and the ilio-femoral arteries. This figure was reproduced with permission [5].  
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The effects of localized disturbed flow have been studied in murine partial ligation 
models, which have become a gold-standard in studying atherosclerotic plaque initiation 
and progression [6, 7]. The model involves ligating the downstream portions of the left 
carotid artery (LCA) (Fig. 1.2A) to allow for the growth of an atherosclerotic plaque in an 
apolipoprotein E knockout mouse (Fig. 1.2B). The partial ligation of the LCA generates a 
disturbed flow profile that initiates the growth of the atherosclerotic plaque, which can be 
analyzed with histology and ultrasound equipment to compare the bidirectional flow 
velocities of the LCA to the unidirectional flow velocities of the right carotid artery (RCA) 
(Fig. 1.2C-F). The development of this mouse model allowed for the screening of 
therapeutic and diagnostic, or theranostic, materials, such as nanoparticles, statins, and 
nucleic acids [8-10]. However, how translatable an animal response to a therapy is when 
compared to a human response is a question that is still brought up due to the 
discrepancies in the results between animal studies and clinical trials [11]. 
 
Figure 1.2. Partial ligation mouse model for disturbed flow-induced atherosclerosis. 
(A) The left carotid artery (LCA) of a mouse is ligated to allow for (B) the growth of an atherosclerotic 
plauqe (red arrow). Scale bar is 1 mm. (C, D) Ultrasound and pentachrome staining can be used 
on the LCA and (E, F) right carotid artery (RCA) to compare the effects of disturbed flow on 
atherosclerotic plaque growth. Scale bar is 100 µm. This figure was adapted with permission [6, 8].  
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Current therapies for CVD patients primarily include dieting, exercise, and the use 
of statins, which are orally administered drugs that competitively inhibit cholesterol 
synthesis in the liver [12, 13]. However, patients who undergo these therapies still risk the 
occurrence of hepatic and/or cardiac related issues, forcing the need to develop additional 
therapies against inflammatory mechanisms that trigger atheroprogression [14, 15]. Of the 
potential therapies currently being studied, high-density lipoproteins (HDLs) have been 
studied for their key contributions to cardiovascular health, which include the regulation of 
lipid homeostasis in the body and their anti-inflammatory effects on the vascular 
endothelium [16, 17]. HDL is one of 5 lipoproteins with a size range of 7-17 nm across 5 
subclasses: (1) very large, (2) large, (3) medium, (4) small, and (5) very small [18-20]. As 
a highly heterogenous nanoparticle, HDL not only spans a range of sizes and densities 
throughout its subclasses, but it also has a diverse proteome and lipidome [19]. The 
primary structural and functional component of HDL is apolipoprotein-A1 (apoA1), which 
is the most abundant protein in the HDL proteome [21-23]. Making up over 70% of the 
HDL proteome, apoA1 stabilizes HDL as it matures and transitions from a discoidal 
structure to a spherical structure upon encapsulation of hydrophobic materials [19]. When 
HDL is in its discoidal configuration, a dimerized apoA1 “double-belt” stabilizes the 
particle; when in its spherical configuration, HDL is stabilized with 3 apoA1 proteins in a 
“trefoil” configuration (Fig. 1.3). This maturation cycle starts in the liver and gut with the 
association of lipid-free apoA1 with phospholipids to form the discoidal nanoparticles, 
often called nascent HDLs [23, 24]. As the nascent HDL internalizes cholesteryls and lipids 
from tissue during circulation, the discoidal structure matures into a spherical particle, a 
characteristic structural change indicating that the core of the particle has been filled with 
hydrophobic materials. The idea of using HDL to combat the effects of CVD was first 
introduced in the Framingham Studies that discovered an inverse correlation between the 
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serum HDL-levels and the incidence of CVD, which paved the way for the “HDL 
Hypothesis” [25-27]. 
 
Figure 1.3. HDL basic structures and components. 
Through a process called HDL maturation, HDL transitions from its discoidal “double-belt” 
configuration to its spherical “trefoil” configuration through the encapsulation of hydrophobic 
materials. The average diameter of the HDL nanoparticle is 10 nm.  
 
The “HDL Hypothesis” poses the idea of raising serum HDL levels to decrease the 
incidence of CVD-related events [27]. In the context of nanomedicine, HDL has emerged 
as a promising option for an endogenous therapeutic delivery vehicle that is stable in 
circulation while intrinsically offering anti-inflammatory and atheroprotective effects [28-
31]. Such effects include promoting of cholesterol efflux known as reverse cholesterol 
transport (RCT), inhibiting of endothelial adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1), and 
functioning as an antioxidant that reduces the atherogenicity of lipoproteins like low-
density lipoproteins (LDL) [32]. It should be noted that the diversity of the HDL proteome 
and lipidome, with over 200 detected types of associated proteins and lipids, has a distinct 
impact on the functionality of HDL [33, 34]. Several HDL-associated components and their 
functions include: (1) cholesterylester transfer protein (CETP) is needed for the exchange 
of triglycerides and cholesteryls between LDLs and HDLs; (2) paraoxonase-1 (PON1) 
provides HDL the enzymatic activity to combat the oxidative modification of HDL; and (3) 
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apolipoprotein-M (apoM) and sphingosine-1-phosphate (S1P) together enable HDL’s 
interaction with S1P-1 and S1P-3 receptors to improve the barrier integrity of endothelial 
cells [33, 35, 36]. With varied levels of functionality that depend on composition, HDLs are 
likely to have heterogenous characteristics that vary between patients [37]. Issues in 
transitioning HDL therapies from benchtop results to clinical practice continue to persist; 
simply raising the HDL serum levels have not conclusively resulted in reducing patient 
CVD outcomes [33, 38-40]. These therapies that focused on raising apoA1 concentrations 
in serum through infusion or oral administration, such as the recombinant apoA1 based 
CER-001 or CETP-inhibiting based Evacetrapib, failed to show regression of 
atherosclerotic plaques in clinical studies [40-42]. It is unclear whether or not the negative 
outcomes from HDL-therapy trials are due to the diversity of the HDL functionality between 
patients, which is a motivation to better understand the contributions of HDL’s functional 
components. In order to achieve this level of understanding, it becomes necessary to 
engineer HDLs with a controlled composition and measure their interactions with living 
systems for translational research.  
The transition of products from benchtop results to their practical usage in society, 
otherwise known as translational research, has come with many challenges since its 
implementation. Among these challenges include the development of medicines for use 
in clinical practice, which typically requires a massive investment of limited resources for 
a relatively low yield in practical results [11, 40, 43]. HDL therapies belong to a class of 
materials known as nanoparticles, therapeutic materials on the scale of 1-100 nm that can 
be engineered for specific applications with the capacity for multiple therapeutic and 
imaging agents [44-47]. Reported applications of HDL-nanoparticles include its use as an 
imaging agent through the incorporation of a gold crystal into the lipid core of an apoA1-
stabilized nanoparticle [48, 49], its applications in gene-therapies through the delivery of 
small interfering ribonucleic acids (siRNA) [50], and through the use of apoA1-mimetic 
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peptides in an attempt to mimic or improve the anti-inflammatory properties of HDL [38]. 
These mimetic peptides, while having no sequence homology with apoA1, are capable of 
forming a class A amphipathic helix similar to those of the lipid binding domain for apoA1. 
The first mimetic peptides for apoA1 were based on an 18 amino acid sequence with 
varying physical and chemical properties; the most commonly known early peptides are 
18A, 2F, 3F, and 4F [38]. Early tests of these peptides showed that it was difficult to detect 
peptide biofunctionality through the evaluation of just the physical and chemical properties; 
the 4F peptide garnered attention for its potential anti-inflammatory applications after 
demonstrations of its ability to induce reverse cholesterol transport from macrophages [51]. 
The positive outlook of the 4F peptide inspired the examination of its reverse sequence 
analog, r4F. The r4F peptide was also found to be able to replicate natural HDL 
functionality through cholesterol efflux assays, and was even used for diagnostic and 
therapeutic application studies in cancer and Alzheimer’s disease [52, 53]. Although the 
r4F peptide’s structure and functionality closely resembled that of natural HDL, a direct 
one-to-one comparison between r4F and apoA1 functionality had not been made. Aside 
from endogenous and synthetic lipoproteins, common forms of nanoparticles include 
liposomes, polymeric-nanoparticles, lipid-polymer nanoparticles, and gold nanoparticles 
[28, 54-56]. Combinations of these common nanoparticle types allows for the tuning of 
nanoparticle properties for specific diagnostic or therapeutic applications that require 
overcoming biological barriers through the fulfillment of certain criteria that include: 
circulation time, payload capacity, and tissue targeting [57]. Alongside the use of 
multiscale animal models, the advancements of translational microtechnology has allowed 
for the development of nanoparticle screening and manufacturing tools using microfluidic 
technology (Fig. 1.4).  
Microfluidic technology encompasses systems that manipulate fluids in microscale 
channels, and this technology has become a foundation in in vitro examinations and 
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controlling microscale reactions [11, 58]. This is possible with the control over the fluidic 
environment that microfluidic-based systems offer [59]. Nanoparticle translation has also 
benefited from microfluidics through high-throughput and continuous production methods 
while maintaining nanoparticle quality as defined by a polydispersity index that describes 
the homogeneity of nanoparticle sizes [11, 60].  
 
Figure 1.4. The scale of translational tools and technologies. 
Translational tools that primarily consisted of animal models and static in vitro assays now include 
microtechnologies that can both screen nanoparticles on a microphysiological level, and that can 
upscale the manufacturing of nanoparticles with micromixing platforms on a parallelizable level.  
 
Microfluidic mixing technologies drive the high-throughput synthesis strategies for 
nanoparticle translation. Microfluidic mixing was first identified as a crucial property to 
early lab-on-a-chip (LOC) or micro total analysis systems (µTAS) due to the necessities 
of intimately mixing reagents in miniaturized reactors for biological, chemical, and medical 
applications [61]. Various mixing strategies, generally divided into passive or active forms 
of mixing, have been studied due to the challenges of mixing in a microenvironment where 
 8 
viscous forces are dominant [62]. The mixing strategies employed in microfluidic platforms 
applied to the enhancement of nanoparticle self-assembly begin to address the challenges 
of nanoparticle batch-to-batch variation, shifting the nanoparticle synthesis paradigm from 
a bulk benchtop scheme to a more continuous and reliable manufacturing scheme [60]. 
Compared to the heterogeneous mixing environment of conventional bulk nanoparticle 
synthesis approaches, microfluidic approaches to nanoparticle synthesis use the small-
scale fluidic interactions to control the fluidic mixing patterns, which results in a greater 
monodispersity of nanoparticles and ultimately reduces the batch-to-batch variation in the 
nanoparticle product. Advantages of microfluidic platforms in reducing nanoparticle 
polydispersity during self-assembly have been demonstrated across multiple mixing 
strategies including diffusion and microvortex formation (Fig. 1.5A and B) [54, 59, 60, 63]. 
The use of microvortices for the self-assembly of nanoparticles allows for higher 
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nanoparticle production rates compared to diffusion-based mixing approaches, which also 
promotes the formation of smaller nanoparticles [54, 63].  
 
Figure 1.5 Microfluidic methods for nanoparticle synthesis. 
(A) A diffusion-based synthesis typically occurs at low Re Numbers (< 1) and utilizes hydrodynamic 
focusing of the nanoparticle precursors to control their diffusion interface. (B) Convection-based 
synthesis occurs at high Re Numbers (> 50) to generate microvortices that can force the 
interactions of nanoparticle precursors while increasing the synthesis rate of the particle. (C) 
Parallelized systems may be implemented to scale-up a single microfluidic platform for industrially-
relevant manufacturing. (D) The general synthesis scheme when implementing microfluidic 
methods for nanoparticle synthesis. This figure was adapted from [60, 63, 64]. 
 
The microfluidic nanoparticle synthesis strategy may also be scaled up through 
parallelized systems that increase the manufacturing rate of the nanoparticles while 
retaining nanoparticle quality (Fig. 1.5C) [64]. It should also be noted that the synthesis 
scheme between microfluidic methods of nanoparticle synthesis remains the same with 3 
key steps: (1) injection of nanoparticle precursors into the microfluidic mixing system, (2) 
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collection of the nanoparticle mixture from the microfluidic system, and (3) purification of 
the nanoparticles from the precursor mixture (Fig. 1.5D). With regards to HDL, its 
microfluidic synthesis with the microvortex approach has not only allowed for HDL’s 
efficient modification with diagnostic and therapeutic agents, but also in the retention of 
HDL’s natural bioactive properties such as cholesterol efflux or the stimulation of 
endothelial nitric oxide [54, 65, 66]. In addition to the synthesis and manufacturing of 
nanoparticles, microfluidic platforms also allow for the implementation of 
microphysiological systems that may integrate various sensors and control systems to 
quantify cellular responses to a controllable mechanochemical microenvironment.  
Biomimetic in vitro systems, or organ-on-a-chip systems, have shown 
considerable adaptability by balancing complexity and usability to study key physiological 
functions in a dynamic setting that cannot be offered through traditional static culture 
techniques [67]. This technique offers the ability to study cellular responses to various 
drugs and compounds in conjunction with mechanical stimuli, and has been used in the 
context of various organs including the lung, kidney, gut, bone, brain, heart, blood 
vasculature, and liver [67-73]. Devices for examination of endothelial and epithelial cell 
response to various mechanical and chemical stimuli have used the electrical resistance 
across the monolayer to monitor the endothelial barrier integrity [69, 73-76]. The electrical 
measurement, or the transendothelial electrical resistance (TEER), relates the 
permeability of an endothelial monolayer to the resistance across the endothelial 
monolayer in units of   cm2. As the endothelial cells proliferate and establish tight and 
adherens junctions with one another, the TEER value starts to rise before plateauing upon 
monolayer establishment. If the intercellular junctions are disrupted using inflammatory 
factors such as TNF-, the TEER value will drop, reflecting an increase in the permeability 
of the endothelial layer [73]. Incorporation of this technique in a microfluidic platform for 
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examination of nanoparticle interactions with the endothelium allows for quantitative 
measurements for various therapies that may restore endothelial function. The confluence 
of microfluidics and biomimetic design has enabled accurate, high-throughput 
microenvironments for high-impact applications including the characterization of drug 
candidates in clinical studies, reducing the number of costly and highly variable in vivo 
animal models which may differ from the human response [77], as well as improving 
understanding of cellular responses to specific stimuli which prove difficult to monitor in 
vivo. Advances in in vitro model systems, such as 3D cell culture models with advanced 
materials (e.g. hydrogel), have contributed to a better understanding of the function of 
human cells and tissues in physiologically relevant environments [78].  
 
Figure 1.6. Engineering living systems on chips. 
Mechanical and chemical cues may be controlled to tune the cellular microenvironment to mimic 
key in vivo conditions critical to tissue-specific cellular function. These tissue-specific 
microenvironments may be coupled together to develop interconnected systems for the realization 
of human-on-a-chip platforms for comprehensive drug screening applications.  
 
However, the reproduction of physiologically critical features including dynamically 
changing mechanical, chemical, and electrical cues to recapitulate fully functional organs 
still poses technical challenges in the replication of living systems (Fig. 1.6) [79]. 
Developing physiologically accurate in vitro model systems requires precise control of the 
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dynamic properties at a scale comparable and applicable to human cells, tissues, and 
organs. Microfluidic technology is well-suited for these model systems by providing precise 
control over essential model components, including fluid flow, mechanical support, 
chemical factors, and electrical signals in a dynamically changing cellular 
microenvironment [80]. For example, compartmentalized microfluidic systems that allow 
independent control of defined cellular environments have been used in an attempt to 
reconstitute primary structure and function of human organs [81]. Recent development of 
model systems that mimic human organs include recapitulating the lung [82], the gut [83], 
the blood vessels [84], the liver [85], the kidney [86], bone [87], the brain/CNS (e.g. 
neurons-on-a-chip [88]), and muscle [89]. Development of these devices is a high-impact 
research area for drug screening in translational medicine and for advanced tissue 
engineering in regenerative medicine [90]. To better replicate the structure, function, and 
physiology of human organs, engineering living systems on chips includes the 
transformative combination of existing technologies from current functional cell and tissue-
level test-beds to integrated organ and organism-level platforms.  
Despite the potential benefits to fulfilling translational challenges with microfluidic 
technology, the implementation of microfluidic platforms in the development of 
nanomedicines is not common due to challenges that are characteristic to a developing 
technology: (1) a lack of accessibility to specialized tools and skills, and (2) non-
standardized protocols for how to implement microfluidic platforms between research 
groups [11, 91]. The typical fabrication process for microfluidics relies on techniques 
adopted from the fabrication of micro-electro-mechanical systems (MEMS), which often 
requires a cleanroom facility with a spin coater and a photomask aligner [92]. In short, the 
common fabrication steps of a microfluidic device are to (1) spin coat a photocurable 
polymer onto a silicon wafer, (2) use the photomask aligner to cure the polymer to for a 
positive mold of the microchannels, (3) mold poly(dimethylsiloxane) (PDMS) to the 
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patterned silicon wafer to pattern the microchannels into the (PDMS) [92]. Beyond the 
basic fabrication techniques for microfluidic platforms, there is little standardization for the 
design and implementation of microfluidic devices for applications like nanoparticle 
synthesis or biomimicry of the cellular microenvironment. This lack of standardization and 
accessibility to microfluidic technology motivates this study to apply microfluidics to 
various processes in the translational pipeline within the context of disease. 
 
1.2 RESEARCH OBJECTIVES 
 
The primary objective of our study is to expand our understanding in the 
engineering of microfluidic translational tools to aid in the synthesis and screening of 
nanoparticles. We chose to specifically study engineered HDL-mimetic nanoparticles 
(eHNPs) in the pathophysiological context of CVD due to HDL’s endogenous interactions 
with endothelial cells to promote an anti-inflammatory cellular response. Studying specific 
cellular responses to various HDL-components will be achievable not only through the 
precursor-dependent microfluidic synthesis of eHNPs, but also through high-resolution 
imaging and endothelial permeability measurements unique to in vitro microphysiological 
systems. To achieve our primary objective, the study is divided into the following aims: 
1. Detect the functional differences of microfluidically engineered HDL-mimetic 
nanoparticles. 
2. Engineer a microphysiological system to detect and monitor the endothelial response 
to a mechanically stimulated CVD pathology.  
3. Probe the impact of oscillatory shear stresses on HDL-mimetic nanoparticle 
interactions with the endothelium. 
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CHAPTER 2. DETECTING THE FUNCTIONAL DIFFERENCES 
BETWEEN HIGH-DENSITY LIPOPROTEIN MIMETICS 
2.1 ABSTRACT 
 
High-density lipoprotein (HDL) is a key regulator of lipid homeostasis through its 
native roles like reverse cholesterol transport. The reconstitution of this natural 
nanoparticle (NP) has become a nexus between nanomedicine and multi-disease 
therapies, for which a major portion of HDL functionality is attributed to its primary 
scaffolding protein, apolipoprotein A1 (apoA1). ApoA1-mimetic peptides were formulated 
as cost-effective alternatives to apoA1-based therapies; reverse-4F (r4F) is one such 
peptide used as part of a nanoparticle platform. While similarities between r4F- and 
apoA1-based HDL-mimetic nanoparticles have been identified, key functional differences 
native to HDL have remained undetected. In the present study, we executed a 
multidisciplinary approach to uncover these differences by exploring the form, function, 
and medical applicability of engineered HDL-mimetic NPs (eHNPs) made from r4F (eHNP-
r4F) and from apoA1 (eHNP-A1). Comparative analyses of the eHNPs through 
computational molecular dynamics (MD), advanced microfluidic NP synthesis and 
screening technologies, and in vivo animal model studies extracted distinguishable eHNP 
characteristics: the eHNPs share identical structural and compositional characteristics 
with distinct differences in NP stability and organization; eHNP-A1 could more significantly 
stimulate anti-inflammatory responses characteristic of the scavenger receptor class B 
type 1 (SR-B1) mediated pathways; and eHNP-A1 could outperform eHNP-r4F in the 
delivery of a model hydrophobic drug to an in vivo tumor. The biomimetic microfluidic 
technologies and MD simulations uniquely enabled our comparative analysis through 
which we determined that while eHNP-r4F is a capable NP with properties mimicking 
natural eHNP-A1, challenges remain in reconstituting the full functionality of NPs naturally 
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High-density lipoprotein (HDL) is an endogenous nanoparticle (NP) with anti-
inflammatory properties and carrier capabilities. With an average diameter of 7-17 nm, 
HDL naturally transitions between spherical and discoidal configurations with the 
encapsulation and removal of cholesterols or other hydrophobic molecules from its 
hydrophobic core [33]. The impact of HDL and its transitioning structure is largely 
attributed to the functions of its primary protein component, apolipoprotein A1 (apoA1), 
which serves both as a scaffold to bind free lipids and cholesterols and as an agonist for 
anti-inflammatory processes like reverse cholesterol transport (RCT) from macrophages 
and the production of endothelial nitric oxide (NO) [33]. The most common receptors 
involved in the apoA1-stimulated regulatory processes include scavenger receptor class 
B type 1 (SR-B1), ATP-binding cassette transporter subfamily A member 1 (ABCA1), and 
ATP-binding cassette transporter subfamily G member 1 (ABCG1); while ABCA1 and 
ABCG1 are primarily attributed to RCT from macrophages, SR-B1 has been shown to be 
involved in both pathways of RCT and endothelial NO production [93]. Being a natural 
transporter for hydrophobic materials with the added anti-inflammatory benefits, HDL 
became a prime candidate for transporting therapeutic and diagnostic, or theranostic, 
agents for a variety of applications [56, 94]. These applications have been applied to 
engineered NPs mimicking the form and function of HDL, allowing for the additional benefit 
of controlling the NP composition. Simplifying the complex lipidome and proteome of HDL 
to apoA1 and phospholipids, the development of HDL-mimetic NPs first started with direct 
proteo-lipidic self-assembly or the sodium cholate dialysis methods to reconstitute HDL 
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(rHDL) [95], and has more recently incorporated microfluidic methods for a single-step 
assembly approach [54].  
The engineering of HDL-mimetic NPs should involve a combination of 
computational and experimental approaches to comprehensively understand the form and 
function of the resulting NPs. For instance, the discoidal structure of HDL is often 
presented in a double-belt configuration, which has been commonly implemented in 
computational models of HDL self-assembly and is used to explain the structural stability 
of HDL [96-98]. Engineering HDL-mimetics has also resulted in the development of many 
apoA1-mimetic peptides for synthetic theranostic platforms to be used against diseases 
like cardiovascular disease (CVD), Alzheimer’s disease, diabetes, and cancer [38, 99]. 
Compared to apoA1, which has more than 240 amino acids, apoA1-mimetic peptides are 
not sequence homologous and are 18-22 amino acids in length to make the class-A 
amphipathic helical motif from the apoA1 lipid binding domain (Fig. S2.1) [38]. These 
mimetic peptides are also relatively cost-effective synthetic alternatives to apoA1, the 
purification and use of which requires difficult and expensive tests to ensure that human 
plasma (from which natural apolipoproteins are purified) is infection and endotoxin free 
[100]. Of the mimetic peptides studied, reverse-4F (r4F) has shown promising results in 
vivo in combatting the pathogenesis of atherosclerotic mouse models, and in the delivery 
of drug therapeutics [52, 99, 101-103]. The development of r4F was spurred by the varied 
properties among the 4F and r4F mimetic peptides, of which r4F was engineered to 
combine the bioavailability of 4F with different lipid-binding and anti-inflammatory 
properties that were demonstrated in mouse models [101]. NPs formulated with r4F have 
already shown HDL-like structures and reactivity with the receptor SR-B1 for various 
theranostic applications [52, 99]. However, a direct comparison of r4F to apoA1 in the 
context of NP form, function, and drug delivery potential has yet to be conducted.  
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The applications promised in NP therapies show broad reaches inclusive of 
imaging agents for targeted areas in the body and treatments for various diseases. With 
an extensive library of possibilities, different methods have been used to synthesize NPs 
based on lipids, polymers, proteins/peptides, and their combinations [47]; the most 
common method is to use bulk benchtop mixing to enhance NP self-assembly, or the 
spontaneous organization of NP precursors. A major challenge associated with this bulk 
synthesis technique is the resultant high batch-to-batch variation of the NP 
physicochemical properties. To address this challenge, microfluidic technology has 
brought a new synthesis strategy presenting a continuous production platform for highly 
uniform NPs assembled through controlled mixing patterns (diffusive or convective 
means) [63], which facilitate precursor microscale interactions that were not achievable 
through traditional macroscale (centimeter to millimeter) benchtop synthesis techniques. 
Additional critical barriers to translational studies for nanomedicine arise from the 
inability of conventional experimental model systems to conduct mechanistic studies of 
NP interactions with cells in pathophysiologically relevant microenvironments. Microfluidic 
technologies also offer a method through which to screen NP interactions with a biological 
microenvironment through in vitro microengineered physiological systems. These in vitro 
platforms, otherwise known as “organ-on-a-chip” systems, are capable of more accurately 
replicating the physiological tissue environment over traditional in vitro assays through the 
inclusion of key parameters needed for appropriate cellular functionality [104]. In the case 
of NPs delivered intravenously, studies examining the interactions between NPs and 
blood-vascular components are of great importance. Substantial research has presented 
3D co-culture systems of vascular endothelial cells (ECs) and mural cells (e.g., smooth 
muscle cells, pericytes, fibroblasts) with a lumen structure that improves the physiological 
relevance over non-lumen based models [105]. With such a platform commonly used to 
study endothelial responses such as permeability and angiogenesis [106, 107], probing 
 18 
the capacity of HDL-mimetics to exert hallmark properties of HDL, such as stimulating the 
production of endothelial NO [108], is a critical step in their comparative analysis.  
In this work, we conducted a comparative analysis between the use of apoA1 and r4F 
in HDL-mimetics. We first developed and implemented a novel microfluidic platform with 
which to synthesize engineered HDL-mimetic NPs (eHNPs) made from r4F and apoA1. 
Through the combined results of experimental and computational NP characterization 
techniques, our findings initially drew parallels across the various physical and chemical 
properties shared between the eHNPs including NP structure, size, stability, and 
composition. We then applied an innovative translational nanomedicine approach by 
pairing a microengineered vasculature system to screen eHNP function in vitro with a 
murine model to examine eHNP drug delivery to vascularized tumors in vivo. Our initial 
comparisons included eHNP interactions with cells that commonly interact with HDL; we 
then probed eHNP interactions with macrophages and ECs in the context of prevalent 
diseases such as CVD and cancer for the purposes of delivering incorporated theranostic 
agents. Analyzing the computational and experimental results unraveled distinct 
differences between the eHNPs that were tied to NP stability and the mimicry of hallmark 
HDL functions linked to the SR-B1 pathway.  
 
2.3 RESULTS AND DISCUSSION 
 
eHNPs share similarities in form, but they have distinct temporal differences 
The engineering of NPs benefits from incorporating both computational and 
experimental methods to comprehensively understand the similarities and differences 
between different NP formulations. Comparisons between eHNP-A1 and eHNP-r4F made 
through molecular dynamics (MD) simulations showed similar discoidal structures for the 
self-assembled NPs (Fig. 2.1A). Transmission electron microscopy (TEM) micrographs 
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also showed discoidal structures for both eHNP-A1 (Fig. 2.1B) and eHNP-r4F (Fig. 2.1C), 
the stacking structures of which were artifacts of the negative staining techniques in 
preparing the eHNPs for TEM imaging [109]. The synthesis of the eHNPs was 
accomplished using our new microfluidic platform that contains a micropost array to induce 
the generation of microvortices that propagate down the length of the channel to increase 
the overall mixing efficiency of the platform (Fig. 2.1D). This microvortex propagation mixer 
(µVPM) mixed the precursor solutions more efficiently than our previous approach [54] to 
form eHNPs with a physiological composition with the addition of the micropost array (Fig. 
S2.2). With this increased mixing efficiency, synthesizing eHNPs with the µVPM resulted 
in highly reproducible and uniform sizes that were more physiologically relevant to natural 
HDL; the µVPM yielded particles closer to 10 nm with no lipid aggregates whereas the 
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platform without microposts yielded NPs greater than 20 nm (Fig. 2.1E). Both eHNPs not 
 
Figure 2.1. Comparison of engineered HDL-mimetic nanoparticles made from apoA1 or r4F. 
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(A) Molecular dynamics simulations show that 2.3 kDa peptide r4F self-assembles with lipids to 
produce discoidal eHNPs similar to those made with the 28 kDa apoA1 (scale bar is 2.5 nm). (B, 
C) TEM images of the synthesized eHNP-A1 (B) and eHNP-r4F (C) particles (scale bar is 25 nm). 
(D) A microvortex propagation mixer was engineered for the enhanced assembly of the NPs. (E) 
DLS size distribution of eHNPs synthesized with (+) and without (–) microposts. (F) DLS size 
distributions of the produced eHNPs. (G) Protein/lipid compositions of the produced eHNPs (n = 3). 
(H) Stability of the produced eHNPs at 4ºC after 7 days post synthesis. (I) eHNP-r4F aggregation 
over time in a 30 nm simulation box with a trajectory of 3 µs. Plotted as mean ± SEM. 
 
only shared this physiological size when synthesized, but they also shared a physiological 
protein-lipid composition [17]; eHNP-A1 and eHNP-r4F, with average diameters of 10.1 
and 11.7 nm respectively (Fig. 2.1F), both had a composition of 65% protein and 35% lipid 
(Fig. 2.1G). However, in terms of size stability, eHNP-A1 was more stable over the course 
of a week compared to eHNP-r4F (Fig. 2.1H). The lower size stability of eHNP-r4F may 
be attributed to the aggregation of eHNP-r4F over time, which is consistent with MD 
simulations (Fig. 2.1I). The tendency of eHNP-r4F to aggregate may be due to the shorter 
18 amino acid peptide length compared to the 240+ amino acids of apoA1. The impact of 
this difference is shown in the configuration of the scaffolding proteins in the MD 
simulations; eHNP-A1 consisted of two apoA1 proteins horizontally wrapped around the 
perimeter of the particle, whereas the smaller r4F peptides in eHNP-r4F were more 
vertically aligned around the perimeter of the particle. The shorter length of the peptides 
may facilitate a more dynamic exchange of lipids and peptides between particles that can 
cause particle aggregation.   
 
eHNP reactivity is shared with macrophages, but not with ECs 
With natural HDLs most notably interacting with macrophages and ECs [33], we 
examined eHNP interactions with these cell types to compare the bioreactivity of eHNP-
A1 and eHNP-r4F. Both eHNP-A1 and eHNP-r4F were taken up by J774a.1 macrophages 
to a similar extent (Fig. 2.2A and B), however eHNP-A1 induced 15% more cholesterol 
 22 
efflux compared to that of eHNP-r4F (Fig. 2.2C). Competition assays for endothelial and 
 
Figure 2.2. Comparison of eHNP bioactivity. 
(A) DiO-labeled (green) eHNP uptake by DAPI (blue) labeled J774a.1 macrophages (scale bar is 
20 µm). (B) eHNPs uptake quantified with fluorescence intensity (n = 4). (C) Cholesterol efflux with 
eHNPs (n = 3). (D) eHNP-A1 and rhodamine-DMPE labeled eHNP-r4F (red) competitive uptake by 
DAPI (blue) labeled J774a.1 macrophages or HUVECs (scale bar is 50 µm). (E, F) Comparison of 
eHNP-r4F retention by J774a.1 macrophages (E) and HUVECs (F) (n = 4). Plotted as mean ± SEM 
where *, **, and *** are for p < 0.05, 0.01, and 0.001 respectively. 
 
macrophage uptake of eHNP-A1 and eHNP-r4F also showed distinct difference between 
these 2 cell types (Fig. 2.2D); while J774a.1 macrophages showed a gradual decrease in 
uptake of rhodamine-labeled eHNP-r4F with the introduction of eHNP-A1 (Fig. 2.2E), 
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human umbilical vein ECs (HUVECs) showed more than a 2-fold decrease in eHNP-r4F 
uptake when adding an amount of eHNP-A1 equivalent to just half the amount of eHNP-
r4F (Fig. 2.2F). While ECs and macrophages share certain HDL receptors such as SR-
B1, ABCA1, and ABCG1, macrophages express more scavenger receptors, such as 
scavenger receptor class A (SR-A) [93], that allow macrophages to exhibit uptake 
characteristics that are less selective than those of ECs. This lack of selectivity may 
contribute to the lack of retardation in the J774a.1 uptake of eHNP-r4F with the addition 
of eHNP-A1. In addition, the differences between eHNP reactivity may be tied specifically 
to the receptor SR-B1 as seen with the differences in the cholesterol efflux measurements 
(Fig. 2.2C). Although the amino acid sequences between murine and human SR-B1 are 
80% homologous, it should be noted that both murine and human models are appropriate 
for studying human lipoproteins [110, 111]. Since inhibition of SR-B1 in ECs does not 
necessarily completely inhibit the uptake of eHNPs due to redundant HDL uptake 
pathways [112], we determined it was necessary to examine hallmark endothelial 
responses to HDL that are classically stimulated through SR-B1 triggered pathways: the 
production of endothelial NO and its downstream anti-inflammatory effects [108].  
 
Anti-inflammatory endothelial responses are more prominent with eHNP-A1 
To further explore the preferential endothelial uptake of eHNP-A1 over eHNP-r4F, 
we used a microengineered vascular system (Fig. 2.3A) to measure 2 hallmark markers 
to quantify endothelial inflammation: the levels of endothelial NO production and the 
expression of intercellular adhesion molecule 1 (ICAM-1) [106]. While the responses of 
the microvascular network to the eHNPs were similar across all measurements for both 
eHNP-A1 and eHNP-r4F, the responses were more underscored in the cases of eHNP-
A1 exposure. Both eHNPs were able to significantly stimulate endothelial NO synthase 
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(eNOS) and promote NO production, however eHNP-A1 elicited more than double the NO 
 
Figure 2.3. Endothelial response to eHNPs in microengineered vascular system. 
(A) A schematic of a microengineered vascular system (Scale bar is 500 µm) that was used to 
screen the endothelial responses to eHNP-A1 and eHNP-r4F (Scale bar is 100 µm). (B-D) The 
endothelial responses to eHNP-A1 and eHNP-r4F were compared through nitric oxide (NO) 
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production (B) and ICAM expression (C) with and without the presence of TNF-α (D) (Scale bar is 
100 µm, n = 4-8). Plotted as mean ± SEM where * and **** are for p < 0.05 and 0.0001 respectively. 
 
levels compared to the levels eHNP-r4F stimulated (Fig. 2.3B). A primary marker of the 
endothelial inflammatory process is with the expression of surface adhesion proteins; 
endothelial cells activated through mechanochemical stimuli such as oscillatory shear 
stress or inflammatory cytokines like tumor necrosis factor α (TNF-α) express several 
adhesion proteins, including vascular cell adhesion molecule (VCAM-1), ICAM-1, and E-
selectin [33]. The ability of HDL to inhibit cytokine-induced adhesion molecule expression 
has been demonstrated in the protective function against the development of 
atherosclerosis [113]. As seen with apoA1-based reconstituted HDLs (rHDL), both eHNPs 
did not trigger ICAM-1 expression (Fig. 2.3C) and were able to significantly reduce ICAM-
1 levels induced with TNF-α stimulation (Fig. 2.3D) [114, 115]. In line with the magnified 
effects of eHNP-A1 on NO production however, the reduction of ICAM-1 was more than 
twice as prominent with eHNP-A1. These results are consistent with the competition assay 
(Fig. 2.2F) in that HUVECs responded more preferentially in the uptake of eHNP-A1 over 
eHNP-r4F. While both eHNPs could trigger SR-B1 related processes in ECs, eHNP-A1 
outperformed eHNP-r4F in the magnitude to which these processes were stimulated.  
 
DOX delivery to HL-60 is facilitated with eHNPs 
The use of HDL and HDL-mimetics for therapeutic and diagnostic multi-disease 
applications is widely being explored due to its natural role as a stable transport vehicle 
for hydrophobic materials through the body [52, 94]. In the case of chemotherapeutics, 
patient treatments employing anthracyclines have been connected to cardiovascular side 
effects such as acute ischemic heart disease that are typically a result of atherosclerosis 
[116]. With the known cardioprotective properties of apoA1 and HDL, we examined the 
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drug delivery potential of eHNP-A1 and eHNP-r4F in the context of delivering 
 
Figure 2.4. Incorporating DOX into eHNPs for in vitro delivery. 
(A) DLS comparison of eHNP-A1-DOX and eHNP-r4F-DOX to eHNP-A1 and eHNP-r4F 
respectively. (B, C) Mass (B) and efficiency (C) of DOX loading into eHNPs (n = 3). (D) Co-
localization of eHNP (green) and DOX (red) signal in HL-60 cells after 4 h of incubation (Scale bar 
is 5 µm). (E) Nuclear area of HL-60 cells in response to 4 h DOX treatment (n = 5-14). (F) Cancer 
cell (HL-60) viability after a 24 h incubation with DOX treatment (150 ng of DOX) (n = 3). Plotted as 
mean ± SEM where *, **, ***, and **** are for p < 0.05, 0.01, 0.001, and 0.0001 respectively. 
 
anthracyclines. As a proof of concept for this notion, we incorporated a widely used 
anthracycline cancer drug, doxorubicin hydrochloride (DOX), into the eHNPs for which the 
resulting size distributions interestingly yielded similar peaks at 40 nm when adding equal 
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initial amounts of DOX to the synthesis of both eHNP types (Fig. 2.4A). Again, it is 
interesting that eHNP-r4F-DOX had the same size as eHNP-A1-DOX that uses a 10X 
larger scaffolding protein to incorporate this model drug. To confirm the presence of DOX 
in our eHNPs, we found that eHNP-A1-DOX had an improved loading concentration and 
encapsulation efficiency over eHNP-r4F-DOX with efficiencies of 1.5% and 0.5% 
respectively (Fig. 2.4B and C); the encapsulation efficiency, without additional conjugation 
between drugs and NPs, was comparable to values reported by other studies for HDL 
platforms used for drug encapsulation [56]. The discrepancy in DOX incorporation 
between eHNP-A1-DOX and eHNP-r4F-DOX may be a result of the weaker stabilizing 
intermolecular forces of r4F than those available to apoA1 [98]; this difference in stability 
was also observed with drug-free eHNPs in the context of size stability (Fig. 2.1H).  
Having diseases treated with anthracyclines in mind, we cultured acute myeloid 
leukemia (AML) HL-60 promyeoblasts and administered our newly synthesized eHNP-
DOX with either r4F or apoA1 and an equivalent amount of DOX. The examination of the 
short-term (4 h) uptake of eHNP-A1-DOX and eHNP-r4F-DOX by HL-60 cells showed the 
eHNPs and DOX fluorescent signals co-localized primarily in the same region of the cell 
cytoplasm (Fig. 2.4D). Compared to the naked DOX case for which DOX translocated into 
the nucleus, our eHNPs facilitated the delivery of DOX into this cancer cell with slower 
translocation of DOX into the nucleus [117]. It should also be noted that the HL-60 cells 
treated with naked DOX and eHNP-A1-DOX exhibited more swollen nuclei than the HL-
60 cells treated with eHNP-r4F-DOX and saline (Fig. 2.4E); nuclear swelling is a 
characteristic of DOX treatment [118]. This difference in HL-60 morphology may be due 
to a difference in uptake between eHNP-A1-DOX and eHNP-r4F-DOX, for which we tested 
the cytotoxicity of the eHNPs. Over the course of a 24 h culture, we found significant drops 
in the HL-60 cell viability with eHNP-r4F-DOX and eHNP-A1-DOX (Fig. 2.4F). The 
cytotoxicity to the HL-60 cells proved to be more significant with eHNP-A1-DOX than with 
 28 
eHNP-r4F-DOX, which was consistent with the DOX-induced nuclear effects that were 
observed in the confocal microscopy results. 
To further explore the capabilities of both eHNP-A1 and eHNP-r4F in the context 
of drug delivery, we studied the tumor uptake of near-infrared (NIR) dye labeled eHNPs 
delivering DOX in a murine xenograft tumor model of HL-60 cells. The biodistribution of 
the eHNPs with DOX measured using an in vivo imaging system (IVIS) showed a distinct 
difference in the distribution between eHNP-A1-DOX and eHNP-r4F-DOX; eHNP-A1-DOX 
accumulation was significantly higher in the lung, kidney, spleen, and the tumor (Fig. 2.5A). 
Confocal imaging of the cyrosectioned tumor samples showed less delivery of DOX to the 
tumor site with the naked DOX treatment compared to the eHNP-DOX treatments (Fig. 
2.5B), between which eHNP-A1-DOX treated mice showed the highest particle (Fig. 2.5C) 
and DOX (Fig. 2.5D) uptake by the tumor. The co-localization of eHNP and DOX signals 
in the tumor sections (Fig. 2.5B) was also consistent with the in vitro results (Fig. 2.4D). 
The discrepancy between eHNP-A1 and eHNP-r4F accumulation in the tumor may be 
dependent on the interactions between the eHNPs and the tumor microenvironment, 
which has been shown to be especially important in tumor growth through processes like 
angiogenesis [119].  
Our previous work has shown that eHNP-A1 can interact with the endothelium to 
modulate the angiogenic process [107]. It has also been shown that the HDL-sensitive 
receptor SR-B1 is overexpressed in some cancers including myeloid leukemia [120]. 
Potential modes of SR-B1 mediated eHNP tumor retention include interactions with the 
tumor endothelium or the HL-60 tumor cells [93]. Thus, the differences between eHNP-
A1-DOX interactions with the tumor over those of eHNP-r4F-DOX may be due to 
increased EC and/or HL-60 tumor cell interactions with eHNP-A1, which was already 
demonstrated with our in vitro results (Fig. 2.2-4). In addition, the lower stability of eHNP-
r4F we found (Fig. 2.1H and I) may have affected the functionality through eHNP-r4F  
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Figure 2.5. eHNP-facilitated DOX delivery to xenograft tumor in a murine model. 
(A) Biodistribution of DiR labeled eHNPs loaded with DOX (n = 7). (B) Confocal images of DiR 
labeled eHNPs (pseudo-colored green) and DOX (red) in DAPI (blue) labeled HL-60 tumor sections 
(scale bar is 50 µm). (C) Biodistribution of eHNPs to the tumor site (n = 7). (D) DOX fluorescence 
intensity measurements in tumors (DOX: n = 4; eHNPs: n = 7). Plotted as mean ± SEM where *, 
***, and **** are for p < 0.05, 0.001, and 0.0001 respectively. 
 
aggregation in vivo, resulting in a different pharmacokinetic profile in the biodistribution of 
eHNP-r4F-DOX. Therefore, while r4F has potential in disease theranostics through the 
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retention of some of apoA1’s properties, the challenge remains in fully mimicking the 
complex functions of apoA1 and other HDL associated proteins to stimulate key functional, 




HDL-mimetics offer a multitude of avenues through which to explore disease therapy. 
We found that eHNP-r4F was comparable to eHNP-A1 in the basic physicochemical 
properties: size, structure, and composition. However, eHNP-A1 could elicit cellular 
responses such as cholesterol efflux from macrophages and NO production in ECs at a 
higher level than eHNP-r4F. When further compared to eHNP-r4F, eHNP-A1 more 
preferentially interacted with HUVECs and significantly reduced TNF-α stimulated ICAM-
1 expression in the microvascular networks. In the context of drug delivery, eHNP-A1 was 
also better able to incorporate and deliver DOX to the tumor cells in vitro and in vivo. 
However, it should be noted that eHNP-r4F was still able to deliver more doxorubicin to 
the tumor site over the naked DOX treatment in vivo. More studies are needed to elucidate 
the possibilities of using apoA1-based nanocarriers like our eHNPs, as the development 
of apoA1-mimetic peptides such as r4F may be able to serve as a cost-effective alternative 
to apoA1. However, it is clear from our study that apoA1 has many properties that cannot 
yet be fully recapitulated using the apoA1-mimetic peptide r4F. Additional future work to 
be considered would be in the incorporation of other HDL-associated proteins and small 
molecules that modulate the functionality of HDL. By leveraging the combined insights 
provided from experimental and computational approaches, we may examine the 
functionality of eHNPs with these added components to further analyze one of the most 





eHNP synthesis materials 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dimyristoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rhodamine-DMPE) 
were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). The near-infrared label for 
the eHNPs, 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide (DiR), was 
purchased from Thermo Fisher Scientific (Waltham, MA). ApoA1 from human plasma, 
3,3’-dioctadecyloxacarbocyanine perchlorate (DiO), and DOX were purchased from 
Sigma-Aldrich Co. LLC. (St. Louis, MO). The peptide r4F was purchased from RS 
Synthesis, LLC. (Louisville, KY) using the sequence Ac-FAEKFKEAVKDYFAKFWD [99]. 
Polydimethylsiloxane (PDMS) for fabrication of the µVPM synthesis platform was made 
using the Sylgard 184 silicone elastomer kit purchased from Dow Corning Corporation 
(Auburn, MI).  
 
Molecular dynamics simulations 
The MD simulations were performed using the GROMACS software package [121]. 
The coarse grain model for the simulations was done with the MARTINI coarse grain force 
field for biomolecular systems [122]. Combining the ElneDyn elastic network model with 
the coarse grain molecular force field to maintain the secondary and tertiary structure of 
apoA1, we simulated the self-assembly of eHNP-A1 in a 15 x 15 x 15 nm simulation box 
with a periodic boundary and a trajectory of 500 ns [123]. The initial conditions of the 
simulation involved 2 apoA1 molecules arranged in antiparallel around 160 DMPC lipids 
using the insane method for lipid bilayers [124]. Using the same boundary box size of 15 
x 15 x 15 nm and number of lipids, we initiated 1 µs trajectory eHNP-r4F simulations with 
varying protein:lipid molecular ratios based on our eHNP-A1 simulations and on past 
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simulations using the apoA1-mimetic peptides 18A and 4F (Table S3.1) [125, 126]. To 
examine the aggregation of multiple eHNP-r4F particles, we used the initial conditions of 
a 30 x 30 x 30 nm simulation box and a protein:lipid molecular ratio of 1:16 for a trajectory 
of 3.5 µs [125]. 
 
µVPM design, analysis, and fabrication 
The µVPM was first conceptualized from previous platform designs using the CAD 
software SolidWorks from Dassault Systemes SolidWorks Corp. (Paris, France), after 
which we conducted computational flow studies using the solver SC/Tetra (Software 
Cradle Co., Ltd., Osaka, Japan) [59, 63, 127]. The diffusion coefficient was set for 10-9 
m2/s for a small molecule in water at room temperature as previously determined [61]. 
Fabrication of prototype devices using PDMS allowed us to conduct flow visualization 
studies using phenol red and water imaged with an EVOS FL Auto microscope from 
ThermoFisher Scientific (Waltham, MA). Starting from reference inlet ratios and flowrates 
[54], we adjusted the flowrates of the phenol red and water while simultaneously 
comparing them to results yielded from the computational analysis. To evaluate the mixing 
efficiencies of the µVPM, we used a mixing index to compare the lipid mass fraction 
distributions of the channel cross sections to reduce the under-mixed lipid mass fraction 
at the outlet (Fig. S2.2) [64]. The µVPM uses three inlets and a single outlet, with a height 
of 100 µm, outlet width of 2 mm, and 27 microposts with the dimensions 200 x 400 µm. 
For the device fabrication, SU-8 was spun onto 100 mm silicon wafers to a height of 100 
µm before undergoing photolithography. The wafers were developed and dried before 
casting. PDMS was molded to the patterned silicon wafer using a 10:1 mass ratio of 
elastomer to curing agent before curing at 80°C. Molded devices were then bonded to 




eHNP synthesis and characterization 
The synthesis conditions used for all NPs were with a Reynolds number of 50, 
where the flow ratio between the side streams and the center stream was 5.5:1 
respectively. The NP precursor solutions included a lipid solution that was composed of 
DMPC with a concentration of 2.75 mg/mL in 200 proof ethanol, and a protein solution 
that had either apoA1 or r4F with a concentration of 0.2 mg/mL in PBS (1X, pH 7.4). 
Syringe pumps from Harvard Apparatus (Holliston, MA) were used to pump the solutions 
into the device, from which the mixed solution was collected and then triple washed with 
PBS using a 10,000 M.W. (30,000 M.W. when incorporating DOX or fluorescent labels) 
centrifugal filter from EMD Millipore Corporation (Darmstadt, Germany) at a speed of 3900 
rpm for 20 minutes. The size distribution of the final washed sample was measured with 
a Zetasizer Nano ZS from Malvern Instruments (Worcestershire, United Kingdom). Protein 
and lipid precursor compositions between eHNP-A1 (Fig. S2.3) and eHNP-r4F (Fig. S2.4) 
were tuned to achieve an average size of 10 nm. Fluorescently labeled eHNPs used a 
modified lipid precursor solution with Rhodamine-DMPE, DiR, or DiO as 15% of the total 
lipid mass [52, 102]. Incorporation of DOX into the eHNP was done through mixing the 
protein precursor solution to accommodate a 1 mg/mL solution of DOX in DMSO for a final 
precursor solution containing 0.2 mg/mL of both apoA1 (or r4F) and DOX. The protein-
DOX precursor was then microfluidically mixed with the lipid precursor followed by a triple 
wash in PBS all in the same way as for when synthesizing eHNPs without DOX. eHNP-
DOX samples were placed into black well, clear bottom 96 wells plates and measured 
using the excitation/emission wavelengths of 490/580 nm [128, 129]. Samples were 
measured using with a Cytation 5 plate reader from BioTek (Winooski, VT). The Schiffer-





Samples for TEM were prepared on nickel grids with a formvar coating from 
Electron Microscopy Sciences (Hatfield, PA). The NPs to be imaged were triple washed 
in an ammonium acetate buffer. The NPs were then loaded onto the TEM grids before 
they were negatively stained using a 2% phosphotungstic acid solution (PTA). The final 
samples were then imaged on an HT7700 TEM (Hitachi, Tokyo, Japan) at 120 kV coupled 
with the DigitalMicrograph camera and software suite from Gatan (Pleasanton, CA).  
 
eHNP protein and lipid quantification 
Protein quantification was done using the colorimetric Micro BCA Protein Assay kit 
from ThermoFisher. As per the recommendations from the instructions, SDS (1%) was 
added to all samples to prevent the interference of lipids on the protein measurement. 
Lipid quantification was done using the fluorometric Lipid Quantification Kit (neutral lipids) 
from Cell Biolabs, Inc. (San Diego, CA).  
 
Cell culture 
The macrophage adherent cell line J774a.1 from ATCC (Manassas, VA) was 
cultured in Dulbecco’s Modified Eagle Medium supplemented with 1% penicillin 
streptomycin (PS) and 10% Fetal Bovine Serum (FBS). Human umbilical vein endothelial 
cells (HUVECs) were purchased from Lonza (Basel, Switzerland), and were cultured using 
complete endothelial growth medium 2 (EGM-2). Normal human lung fibroblasts (LFs, 
Lonza) were cultured in Fibroblast Growth Medium (FGM-2, Lonza); cell passages 3-4 
were used for the microengineered vascular experiments. Human promyeoblast 
suspension cell line HL-60 originally purchased from ATCC, cultured in complete medium 
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consisting of Iscove’s Modified Dulbecco’s Medium supplemented with 20% FBS and 1% 
PS. Media was refreshed every 3 days.  
 
eHNP uptake and competition assay 
HUVECs and J774a.1 were cultured for 24 hours in a 96-well plate before triple 
washing with PBS and adding culture media with rhodamine-DMPE labeled eHNP-r4F (20 
µg/mL of protein) and/or eHNP-A1 (0, 10, 20, 50, or 100 µg/mL of protein) overnight at 
37C. The cells were then triple washed with PBS before fixation with 4% 
paraformaldehyde and counter staining with DAPI. Samples were then imaged and the 
fluorescent intensity was analyzed using the Cytation 5 plate reader from BioTek. 
 
Cholesterol efflux assay 
J774a.1 cells were cultured in 96 well-plates (black well, clear bottom) at a density 
of 12,500 cells/well. Plates were cultured for 24 h before adding NBD cholesterol 
(ThermoFisher Scientific) overnight at a concentration of 100 µg/mL. The cells were 
washed the next day with PBS before incubating with 2 mg/mL fatty-acid free albumin 
overnight. Cells were then washed and incubated with eHNPs or BSA for 16 h. 
Supernatant media from each well was extracted and cells were washed with PBS. 
Supernatant and cell samples were measured with a Cytation 5 plate reader from BioTek 
using the excitation/emission wavelengths of 469/537 nm. 
 
Cell seeding in the microengineered vascular system 
A previously reported microengineered vascular system designed to probe 
endothelial cell responses in a 3D vascularized network was used to examine endothelial 
interactions with our eHNPs [65, 106, 131]. To fabricate the devices, SU-8 was spun onto 
100 mm silicon wafers to a height of 100 µm before undergoing photolithography. The 
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wafers were developed and dried before casting. PDMS was molded to the patterned 
silicon wafer using a 10:1 mass ratio of elastomer to curing agent before curing at 80°C. 
Molded devices were then bonded to glass slides using the PDC-32G plasma cleaner 
from Harrick Plasma (Ithaca, NY) for 1 minute. Fibrinogen (Sigma) was dissolved in DPBS 
(w/calcium and magnesium, Gibco), filter-sterilized (0.22 µm pore) and then supplemented 
with aprotinin (0.15 U/mL, Sigma). Fibroblasts were re-suspended in the fibrinogen 
solution (2.5 mg/mL) at a concentration of 8 x 106 cells/mL. The cell solution was mixed 
with thrombin (1 U/mL, Sigma) immediately prior to injection into fibroblast channels. 
Following 3 minutes of polymerization at room temperature. The central channel was filled 
in the same manner as the peripheral channels; HUVECs were introduced into the gel at 
a concentration of 5 x 106 cells/mL instead of fibroblasts. After allowing the gels to 
polymerize for 3 minutes at room temperature, the inlet reservoirs of the cell culture 
medium channels were filled with EGM-2 medium, and then aspirated to fill the 
hydrophobic channels (Fig. S2.5). Following loading all four reservoirs, the microfluidic 
platforms were incubated at 37 ºC for 5 days to allow for microvascular network formation 
(Fig. S2.6). Experiments were conducted under static conditions. 
 
Quantifying endothelial NO production and ICAM expression 
The perfusates were supplemented with L-arginine (5 mM, Sigma) and DAF-FM 
DA (5 µM, Molecular Probes) to support and detect the NO production by HUVECs. The 
levels of NO were quantified via confocal microscopy and the fluorescent intensity was 
analyzed with ImageJ. The background fluorescence of each image was eliminated to 
compare NO levels between different dosage conditions, and the total fluorescence was 
normalized to the 0 µg/mL dosage for comparisons between eHNP-A1 and eHNP-r4F. Z-
stack projections were collected to obtain an average intensity value for each chip. To 
compare the effect of the eHNPs on ICAM-1 expression, each microvascular network was 
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pre-incubated with each dosage of eHNP (0, 1, 10 and 100 µg/mL) for 16 h before 
exposure to TNF-α (50 ng/mL) to maximize inhibition of ICAM-1 expression [114]. During 
TNF-α activation for 4 h, the concentration of eHNP was maintained. The devices were 
then fixed and stained for ICAM-1 expression before comparing the fluorescence intensity 
between the eHNP dosages with confocal microscopy. The fluorescence intensities were 
normalized to the 0 µg/mL eHNP dosage. ICAM-1 expression without TNF-α was 
quantified in the same way with the exclusion of the TNF-α incubation step. 
 
Immunostaining in microengineered vascular system 
For immunofluorescence staining, cells in the device were fixed using 4% PFA for 
15 minutes at room temperature (RT), permeabilized with Triton X-100 (0.15% v/v in PBS) 
for 15 minutes, and then blocked in bovine serum albumin (BSA 3% w/v in PBS) for 1 h at 
room temperature. Monoclonal antibodies specific for human ZO-1 (Alexa Fluor 488) were 
purchased from Thermo Fisher, CD31 (Alexa Fluor 647) were purchased from BioLegend 
and Hoechst 3342 were purchased from Molecular Probes. Mouse monoclonal antibodies 
specific for ICAM-1 (Alexa Fluor 488) were purchased from BioLegend. All the samples 
were washed three times and stored in PBS before imaging.  
 
Cell viability assay 
Trypan blue was used to evaluate the viability of HL-60 cells counted in a Countess 
II FL Auto from Life Technologies. Cells were cultured at 37C in complete medium with 
Iscove’s Modified Dulbecco’s Medium and 20% FBS in a 96 well at a density of 20,000 
cells/well. Viability was measured in triplicate every 24 h after addition of eHNPs and DOX 
at a dosage of 150 ng. The amount of eHNPs to be administered to achieve the 
appropriate DOX dosage was determined through the characterization of DOX loading 
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into the eHNPs (Fig. S2.7). All measurements were normalized to HL-60 cell samples 
cultured without the addition of eHNPs or DOX.  
 
Co-localization of eHNPs and DOX 
eHNPs were synthesized using a rhodamine-DMPE lipid to allow for visualization 
of both eHNPs and DOX. HL-60 cells were incubated with either eHNP-r4F-DOX or eHNP-
A1-DOX for 4 h before being fixed for 15 minutes with 4% PFA at RT and spun onto poly-
l-lysine coated glass coverslips and mounted to glass slides using VectaShield (Vector 
Laboratories, Burlingame, CA) with DAPI counterstain prior to fluorescent imaging with a 
LSM 700 confocal microscope from ZEISS (Oberkochen, Germany) [132, 133]. Images 
were pseudo-colored for consistency through the study; green for eHNPs, red for DOX, 
and blue for DAPI. 
 
Murine xenograft tumor biodistribution of eHNPs 
Nude female balb/c mice were ordered at 5 weeks of age and allowed to acclimate 
to the lab facility conditions for 1 week on an irradiated dietary regiment. Two million HL-
60 cells were injected in 100 µL of PBS into the rear right flank of the mouse. To maximize 
the amount of DOX delivered by the IVIS-trackable eHNPs, increasing amounts of DOX 
were added to the hydrophobic precursor with DiR to find an upper limit of loaded DOX. 
Using the 5:1 mass ratio between DOX and protein, a 200 µL tail vein injection of saline, 
DOX, eHNP-A1-DOX, or eHNP-r4F-DOX was administered to the mouse after its tumor 
reached at least 100 mm3 in volume as measured by digital calipers (Fig. S2.8). The 
dosages for the injections were 5 mg/kg of protein, equivalent to 0.25 mg/kg of DOX. The 
animals were sacrificed and perfused with saline and 4% PFA for 15 minutes at RT 24 h 
after the tail-vein injection to allow for uptake of the eHNPs (12 h half-life for both) into the 
tumor [102, 134]. This 24 h time point was also consistent with the in vitro cytotoxicity 
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assay.  The harvested organs were then imaged for their DiR content using an in vivo 
imaging system (IVIS) from Perkin Elmer (Waltham, MA) (Fig. S2.9). The organ masses 
were measured on a scale, and the biodistribution data was calculated from the IVIS data 
(Fig. S2.10). The tumors were first cryosectioned and mounted onto glass slides using the 
antifade mounting medium with DAPI (H-1200) from Vector Laboratories (Burlingame, CA) 
before being imaged under a confocal microscope (Zeiss LSM 780) [135]. Image analysis 
of the tumors was done using ImageJ for 3 sections per tumor.  
 
Statistical Analysis 
Statistical analyses were run in Prism 7 (GraphPad Software Inc, La Jolla, CA) and 
significance was defined as P < 0.05 (*). Statistical significance analysis was done via t 
tests or ANOVA.  
 





Figure S2.1. Schiffer-Edmunson diagram for r4F and the 10 alpha helices of apoA1. 
The r4F peptide is not homologous to any of the apoA1 helices, however it mimics the class A 
helices that characteristically have a high mean hydrophobic moment with negative charges in the 




Figure S2.2. Engineering the microvortex propagation mixer (µVPM).  
(A) Critical dimensions of the µVPM. (B) Image of µVPM (Scale bar is 4 mm) and the determination 
of critical flow rates to minimize the unmixed lipid stream (white arrow) through experimental flow 
studies with phenol red (Scale bar is 400 µm). (C, D) CFD simulations of the mixing efficiency 
based on the number of microposts in the µVPM. (E) CFD simulations and experimental (EXP) 
results comparing the same platform with 6 rows (+) and 0 rows (–) of microposts through the 
mixing of the precursors given by the hydrophobe mass fraction. (F) A comparison of the simulated 
mixing efficiency of precursors between the platform with 6 rows (+) and 0 rows (–) of microposts 
spanning from the inlets (I) to the outlet (O); values are normalized to the micropost (–) case. (G) 
Protein and lipid quantification of eHNPs made with (+) and without (–) the micropost array (n = 6). 





Figure S2.3. Size distributions of eHNP-A1 
(A) Volume and number frequency distributions are given for the 2.5:1 (lipid:protein) mass ratio 
formulation for eHNP-A1. (B) Various formulations were examined to tune the size of the eHNPs 




Figure S2.4. Size distributions of eHNP-r4F. 
(A) Volume and number frequency distributions are given for the 2.5:1 (lipid:protein) mass ratio 
formulation for eHNP-r4F. (B) Various formulations were examined to tune the size of the eHNPs 




Figure S2.5. Microengineered vascular system components. 
(A) Microengineered vascular system platform incorporates 5 channels; (B) the left outer (LO), left 
inner (LI), center (C), right inner (RI), and right outer (RO) channels. (C) Critical dimensions of the 
microengineered vascular system. (D) Photograph of microengineered vascular system (Scale bar 





Figure S2.6. Microengineered vascular system timeline. 
The HUVECs seeded into the C channel extend to the growth media filled LI and RI channels over 





Figure S2.7. DOX loading measurements. 
(A) Table of measurements for initial DOX loading measurements for Fig. 4. (B) Standard curve for 




Figure S2.8. Preparation for in vivo experiment. 
(A) DOX concentration in eHNPs with increasing DOX:Protein precursor mass ratios for in vivo 
experiments with the addition of DiR (n = 3-6). (B) Tumor volumes exceeded 100 mm3 after growing 
for 15 days (n = 12). (C) Tumor volume difference prior to eHNP tail-vein injection between the 




Figure S2.9. In vivo biodistribution measurements and setup. 
IVIS images 24 hs after tumor-bearing mice were treated with eHNP-A1-DOX or eHNP-r4F-DOX. 
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Figure S2.10. IVIS analysis for nude balb/c mice bearing HL-60 tumors. 
Additional analysis of IVIS data (n = 7). Plotted as mean ± SEM where *, **, ***, and **** are for p 
< 0.05, 0.01, 0.001, and 0.0001 respectively. 
 
 
Table S2.1. Molecular dynamics simulations for eHNP-r4F. 
Molecular dynamics simulations for eHNP-r4F self-assembly based on increasing protein:lipid 
(mol) ratios and the resulting diameters of the particles that are formed (Scale bar is 5 nm). 
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CHAPTER 3. A MICROPHYSIOLOGICAL SYSTEM FOR 




 The endothelial microenvironment is critical in maintaining the health and function 
of the intimal layer in vasculature. In the context of cardiovascular disease (CVD), the 
vascular endothelium is the layer of initiation for the progression of atherosclerosis. While 
laminar blood flows are known to maintain endothelial homeostasis, disturbed flow 
conditions including those the endothelium experiences in the carotid artery are 
responsible for determining the fate of CVD progression. We present a microfluidic device 
designed to monitor the endothelium on two fronts: the real-time monitoring of the 
endothelial permeability using integrated electrodes and the end-point characterization of 
the endothelium through immunostaining. Our key findings demonstrate endothelial 
monolayer permeability and adhesion protein expression change in response to oscillatory 
shear stress frequency. These changes were found to be significant at certain frequencies, 
suggesting that a frequency threshold is needed to elicit an endothelial response. Our 
device made possible the real-time monitoring of changes in the endothelial monolayer 
and its end-point inspection through a design previously absent from the literature. This 
system may serve as a reliable research platform to investigate the mechanisms of various 
inflammatory complications of endothelial disorders and screen their possible therapeutics 
in a mechanistic and high-throughput manner. The contents of this chapter were 
previously published in Scientific Reports [136].  
 
3.2 INTRODUCTION  
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The vascular endothelium is a vessel-lining barrier that controls the transport of 
biologically active molecules and regulates inflammation, blood pressure and clotting, and 
immune cell trafficking. Endothelial homeostasis is critical for maintaining cardiovascular 
health against the onset of diseases that manifest from cardiovascular disease (CVD) 
[137]. Atherosclerosis is one such disease that stems from the chronic inflammation of the 
endothelium [3]. Studies examining the mechanotransduction of endothelial cells have 
linked endothelial inflammatory responses, including adhesion protein expression and 
nitric oxide production, to shear stress magnitude and direction [138-140]. Certain areas 
in the body, like the carotid sinus that has a unique expanding vasculature geometry, have 
localized disturbed flow acting back and forth against the vascular wall with shear stresses 
from < 10-12 dyne/cm2 in humans (Fig. 3.1A) [141, 142]. While endothelial homeostasis 
is maintained in laminar shear stress (LSS) conditions, the prolonged exposure of the 
endothelium to oscillatory shear stress (OSS) caused by disturbed flow leads to the 
chronic inflammatory response, adversely increasing the risk of atherosclerosis and CVD 
initiation [143-145]. Despite the understanding of the role of OSS-induced endothelial 
inflammation in several fatal diseases, challenges remain in sensing the inflamed 
endothelium under pathological blood flow (i.e. disturbed flow) and delivering sufficient 
therapeutic agents. 
The implementation of atherosclerotic animal models has aided in the study of the 
disease progression and development of potential therapy options for the disease [146]. 
One such method to study the atherosclerotic pathology is to use the partial ligation 
surgery of the left carotid artery (LCA) in apoE-/- mice [6] to apply disturbed flow and the 
resulting OSS to the endothelium and accelerate atherosclerotic plaque growth. While 
these findings have improved our understanding of OSS-derived pathology in CVD, further 
progress in this area is hampered by technical challenges of conducting mechanistic 
studies on targeted drug discovery and development in the human vasculature. Moreover, 
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extrapolation of animal data to human conditions has been frustratingly controversial, 
particularly for complex diseases afflicting dynamic microenvironments prevalent with 
mechanochemical stimuli such as blood flow and inflammatory cytokines [104]. 
Overcoming traditional in vitro models that predominantly rely on static culture of vascular 
endothelial cells, current advanced in vitro studies on endothelial mechanotransduction 
have taken the magnitude and direction of OSS into consideration to complement existing 
animal model research [138, 139, 143, 144, 147-149]. The frequencies typically 
associated to be characteristic of disease-causing OSS are based on measured 
physiological values in vivo; this value is about 5 Hz in mice, whereas in humans this level 
drops to approximately 1 Hz [7, 138, 145]. Despite sophisticated approaches to apply OSS 
in vitro, variations in endothelial cell responses to slight changes in the disturbed flow 
pattern may not be adequately reflected for studying certain mechanisms such as the 
dynamic interaction of the vascular endothelium with drugs in vivo [150, 151]. More 
importantly, little work has questioned whether the endothelial response is affected by the 
frequency of OSS, which may be key to influence expression of pro-inflammatory proteins 
like VCAM-1, ICAM-1, or IL-8 [152, 153]. Consequently, emerging technologies like 
biomimetic microfluidic platforms are being developed to address questions like these by 
implementing physiological and pathological conditions in a minimalist in vitro setting of 
OSS-induced vascular complications. 
Microfluidic platforms, some of which are called organ-on-a-chip systems, provide 
an unprecedented ability to control the mechanical and chemical microenvironment in a 
spatial and temporal fashion, enabling the studies of dynamic cellular responses to a 
variety of mechanical and chemical stimuli [154]. The capabilities to measure cellular 
responses from dynamic environments typically found in physiological systems, as well as 
the potential for high-throughput applications, make microfluidic technology a suitable 
medium through which to study shear-dependent endothelial responses with 
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spatiotemporal manners and high precision. Microfluidic platforms have also grown to 
include screening tools to accelerate the development of therapeutics in physiological 
disease settings [11]. We present the design and implementation of a microfluidic 
transcellular monitor to dynamically examine the permeability and adhesion molecule 
expression of an endothelial monolayer to prolonged OSS-exposure of varying 
frequencies. Additionally, we report and address the challenges of widely used existing 
double-layered endothelialized microfluidic platforms; the endothelium near the channel 
wall fails to replicate physiologically relevant endothelial morphology and function in 
response to the application of shear, compromising the accuracy to investigate both the 
effect of mechanical and chemical cues on the endothelium and the translocation of 
nanoparticles across the endothelial barrier [73]. By imposing the accurate shear stress 
on primary human aortic endothelial cells (HAECs), as well as monitoring the endothelial 
permeability, our microfluidic transcellular monitor may provide a simple yet reliable 
platform to: (i) examine the underlying mechanisms by which vascular endothelial 
disorders occur and lead to complicated inflammatory pathologies, and (ii) efficiently test 
the efficacy of potential drug candidates targeting the dysfunctional endothelium in various 
mechanically (shear stress) and chemically (pro-inflammatory cytokines) stimulated 
pathophysiologically relevant conditions. 
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Figure 3.1. Monitoring of the endothelium for flow-based studies. 
(A) Carotid bifurcation areas of LSS and OSS vary due to expanding sinus geometry. (B) A 
microfluidic transcellular monitor for probing endothelial responses to the flow microenvironment is 
capable of collecting both monolayer permeability data through TEER and monolayer images 
through a transparent porous membrane. (C) The device component overview highlighting the 
Ag/AgCl electrode integration directly into the platform to probe the monolayer growing on the 
porous membrane. (D) CFD simulations in the upper microchannel show the distribution of the wall 
shear stress (WSS) and the lower microchannel boundary (dotted line). (E) Cross-section 
schematic of upper and lower microchannels shows where the localization of ICAM should occur 
due to the calculated WSS distribution. (F) Monolayer maturity is determined through stabilization 
of TEER values (N = 3). Plotted as mean ± SEM where * is for p < 0.05. (G) Confocal microscopy 
of an endothelial monolayer stained for adherens junctions (red) and ICAM (green) with DAPI 
counterstaining on a porous membrane with 8 µm pores. Scale bar is 25 µm. 
3.3 RESULTS AND DISCUSSION 
 
Microfluidic transcellular monitor design 
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The microfluidic transcellular monitor platform was designed to study the 
endothelial responses through electrical measurements and microscopy data that track 
the intercellular permeability and overall visual health of the monolayer in a multi-layer 
design (Fig. 3.1B). High-throughput and real-time monitoring of the endothelium was 
accomplished through and array of devices implementing the transendothelial electrical 
resistance (TEER) across the upper and lower microchannels using Ag/AgCl electrodes 
integrated on the device (Fig. 3.1C and Supplementary Fig. S3.1). This double-layered 
microfluidic platform with a high endothelial cell seeding density to allow for the uniform 
coverage of endothelial cells across the microchannel. To address the issue of the non-
homogenous morphological and functional responses of endothelial cells due to their 
proximity to the sharp corner of the microchannel wall and better model the vascular 
endothelium, we performed computational fluid dynamics (CFD) analyses to find that the 
endothelial monolayer would only experience the greatest directional changes in response 
to flow within the middle 50% of the upper microchannel width (Fig. 3.1D). We validated 
these CFD simulation results using human umbilical vein endothelial cells (HUVECs), a 
widely used endothelial cell type in vitro, cultured in the upper microchannel geometry on 
a glass substrate to show nearly a 30% decrease in mean cell area for cells growing in 
the middle of the microchannel under flow, the absence of which resulted in an 
insignificant difference in the mean cell area between the cells growing in the two regions 
(Supplementary Fig. S3.2). Taking into account both the TEER dependency on the 
overlapping area of the upper and lower microchannels and the CFD simulation results, 
the upper microchannel was designed to have twice the width as the lower microchannel 
(200 µm and 100 µm, respectively) so that we could monitor an area that would only 
include the middle 50% region of the upper microchannel (Fig. 3.1E). With this 
microchannel configuration, we were able to efficiently inspect the HAEC monolayer 
growth and maturation using TEER, the leveling-off of which identified the monolayer 
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maturity with high reproducibility (Fig. 3.1F). Visual inspection of the HAEC monolayer 
through confocal microscopy was used in conjunction with TEER to gain a more 
representative understanding over how the endothelial monolayer responded to our flow-
based stimuli (Fig. 3.1G). 
 
Tailored platform more suitable for endothelial response monitoring 
Using this new design that can accurately impose both the specific quantity and 
direction of shear stress on the endothelium cultured in the middle microchannel, we then 
investigated whether our microfluidic transcellular monitor was capable of accurately 
reconstituting pathophysiological conditions caused by shear stress profiles. We first 
cultured HAECs to form a monolayer and get exposed to LSS of +10 dyne/cm2 to 
investigate whether or not there is locally distinct expression of EC proteins in the center 
region (defined as the middle 50% region) of the upper microchannel (Fig. 3.2A). 
Comparing the center region to the remaining area of the upper microchannel (defined as 
the edge region) yielded a non-significant difference in the β-catenin (Fig. 4.2B) and ICAM 
intensity (Fig. 3.2C). We then examined this effect with an HAEC monolayer exposed to 
OSS of +10 and -9 dyne/cm2 at 1 Hz (Fig. 3.2D). The comparison of the center region to 
the edge region yielded a non-significant difference in β-catenin intensity (Fig. 3.2E). 
However, there was nearly double the ICAM intensity expressed in the center region 
compared to that in the edge region (Fig. 3.2F). Following the verification of our simulation 
results with the observation of ICAM localization to the center region of the microchannel, 
the confocal imaging area for comparisons across devices with varying shear stress 
conditions was then defined to only include the center region due to the verified non-
negligible effects of the microchannel wall. In following the same design intent, the choice 
to make the lower microchannel half as wide as the upper microchannel was to minimize 
the effect of the wall on TEER measurements. This is especially important for the accurate 
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monitoring of the endothelial permeability in response to varying shear stress conditions, 
such as shear oscillation frequency, due to the direct influence the overlapping area of the 
upper and lower microchannels has on TEER measurements [75].  
 
Figure 3.2. Microfluidic transcellular monitor design. 
(A) Confocal microscopy images were taken through the underside of the porous membrane of an 
HAEC monolayer cultured in the upper microchannel under LSS at 10 dyne/cm2 that were stained 
for β-catenin and ICAM (lower microchannel outlined with dotted white lines). Scale bar is 40 µm. 
(B) β-catenin channel intensity measurements and (C) ICAM channel intensity measurements for 
the LSS case comparing the center and edge regions normalized to the edge region (N = 3). (D) 
Confocal microscopy images were taken through the underside of the porous membrane of an 
HAEC monolayer cultured in the upper microchannel under OSS at 1 Hz that were stained for β-
catenin and ICAM (lower microchannel outlined with dotted white lines). Scale bar is 40 µm. (E) β-
catenin channel intensity measurements and (F) ICAM channel intensity measurements for the 
OSS case comparing the center and edge regions normalized to the edge region (N = 3). Plotted 
as mean ± SEM where * is for p < 0.05. 
 
Endothelial response is dependent on the OSS frequency. 
The carotid artery is a region of interest in CVD research due to its unique 
geometry to produce locally recirculating or disturbed flows. The shear stresses in these 
regions average to about 10 dyne/cm2, which is a commonly used shear stress value with 
HAECs under laminar flow in vitro [141, 142, 155, 156]. Shear stresses of +10 and +10/-
9 dyne/cm2 were used for the LSS and OSS conditions respectively to minimize variations 
in the flow conditions to be in OSS frequency while still allowing the refreshment of media 
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in the devices. The average shear stress magnitude across the microchannel width 
between the OSS and LSS cases, +1 and + 10 dyne/cm2 respectively, were compared 
through CFD-calculated WSS distributions, β-catenin intensity measurements, and ICAM 
intensity measurements in the center channel region (Fig. 3.3A and B). The HAEC 
monolayers matured in 24 hours under LSS of +10 dyne/cm2 (Fig. 3.1F), after which the 
various shear conditions were imposed for 12 hours (Supplementary Fig. S3.3). Between 
the +1 and +10 dyne/cm2 cases under LSS, the differences in TEER, β-catenin intensities, 
and ICAM intensities were insignificant (Fig. 3.3C-E).  
 
Figure 3.3. Comparing LSS cases for +1 and +10 dyne/cm2. 
(A) Upper microchannel WSS distribution and confocal microscopy of an HAEC monolayer cultured 
under +1 dyne/cm2 and (B) + 10 dyne/cm2 as viewed through the underside of the porous 
membrane. Confocal images used for comparison were taken from a region in the center of the 
upper microchannel (outlined). Scale bar is 40 µm. (C) Normalized TEER of HAEC monolayer 
cultured under +1 or +10 dyne/cm2. (D) β-catenin channel intensity measurements and (E) ICAM 
channel intensity measurements for the LSS cases comparing +1 and +10 dyne/cm2 normalized to 
1 dyne/cm2 case (N = 3). Plotted as mean ± SEM where * is for p < 0.05. 
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The HAEC monolayers were cultured under 0 X (LSS), 0.1 X (OSS), and 1 X (OSS) 
of the 1 Hz OSS frequency typically used in vitro to approximate the average resting heart 
rate of an individual [138]. The immunostaining comparisons showed disruptions in the 
endothelial monolayer and increased ICAM expression for 1 Hz case (Fig. 3.4A and B). 
Measuring the ICAM and β-catenin channel intensities revealed that while there was no 
significant difference in β-catenin expression, the 1 Hz case had a significantly higher 
expression of ICAM (Fig. 3.4C and D). Monitoring of the endothelial permeability revealed 
that the TEER significantly decreased for the HAEC monolayers exposed to OSS of 1 Hz 
compared to monolayers exposed to OSS of 0.1 Hz (Fig. 3.4E). TEER measurements with 
iMAECs instead of HAECs also showed the TEER to drop significantly after passing a 
certain frequency (Supplementary Fig. S3.4).  
 
Figure 3.4. Monitoring of endothelial frequency response. 
(A) Top view confocal images of HAEC monolayer in the center region cultured under 0.1 Hz. (B) 
Top view confocal images  of HAEC monolayer in the center region cultured under 1 Hz with 
disrupted endothelial junction (white arrow). Scale bar is 40 µm and 20 µm for enlarged image. (C) 
β-catenin intensity channel measurements for the OSS cases comparing 0.1 and 1 Hz normalized 
to 10 dyne/cm2 case (N = 3). (D) ) ICAM intensity channel measurements for the OSS cases 
comparing 0.1 and 1 Hz normalized to 10 dyne/cm2 LSS case (N = 3). (E) Normalized TEER of 
HAEC monolayer after 36 hrs of culture under 12 hrs of 0.1 or 1 Hz normalized to the 10 dyne/cm2 





The design of the microfluidic transcellular monitor was based on the rationale that 
the endothelial cells cultured closer to the side walls of the microchannel with a rectangular 
cross section would exhibit different morphologies from experiencing different shear stress 
profiles, specifically in our case, less of the oscillatory fluid flow effects compared to 
endothelial cells cultured in the middle of the channel. Our results change the status quo 
of key design parameters to keep in mind when concerning microfluidic analyses of 
endothelial monolayers; there is now a cause for future double-layer microchannel 
platforms to more carefully take the microchannel configuration into consideration to 
minimize the influence of the microchannel wall on the experiment. With TEER 
measurements depending on the overlapping microchannel area, we took this design 
criteria into consideration by limiting the lower microchannel width to be half that of the 
upper microchannel [75]. The cultures of HUVECs under LSS and of HAECs under LSS 
and 1 Hz OSS were immunostained to validate our rationale and computational results 
with comparisons of mean cell area, β-catenin expression, and ICAM expression between 
the center (middle 50%) and edge regions (remaining 25% area on either side) of the 
upper microchannel.  
Our validations of the insignificant differences between the net shears of +1 and 
+10 dyne/cm2 determined that the differences observed between our cases were due to 
the different flow frequency cases and not in the shear magnitudes. The monitoring of the 
endothelium during different OSS frequencies showed consistent results across both 
human and mouse endothelial cells, indicating that the endothelial sensitivity to OSS 
frequency was not species-limited. Our results also indicate that there is a frequency 
threshold that must be reached in order to stimulate endothelial inflammation with OSS, 
suggesting that there may be a range of frequencies over which endothelial cells will 
respond in a pro-inflammatory manner. While it is still unclear as to what the breadth of 
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this endothelial pro-inflammatory frequency range includes, comparisons of our results 
with prior studies on the risks of resting heart rate and CVD suggest that higher resting 
heart rates, and thus potentially higher OSS frequencies, have higher risks of experiencing 
a CVD-related episode [157, 158].  
Our findings suggest that the inflammatory response of endothelial cells to OSS 
may be triggered by meeting a minimum frequency requirement. We demonstrated the 
design rationale behind our platform to take advantage of its capabilities to detect changes 
in both monolayer permeability and inflammatory marker expression in response to 
changes in OSS frequency. Future work to consider with this device would be to explore 
the extent of the frequency dependency by pairing the device with a more sophisticated 
fluid flow controller to impose high frequency flows, as well as to screen extensive libraries 
of nanomedicines and therapeutics targeting the endothelium to rapidly identify and 
catalogue endothelial responses [159]. The translation of these results across humans 





Materials and chemicals 
The reagent (3-aminopropyl)triethoxysilane (APTES) was purchased from Sigma-
Aldrich Co. LLC. (St. Louis, MO). Polydimethylsiloxane (PDMS) was purchased as Sylgard 
184 from Dow Corning (Midland, MI). The photoresist SU-8 and its developer were 
purchased from MicroChem Corp (Westborough, MA). HAECs and HUVECs were 
purchased from ATCC (Manassas, VA) and ScienCell Research Laboratories (Carlsbad, 
CA) respectively. The iMAECs were generously donated from the lab of Dr. Hanjoong Jo. 
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Microfluidic transcellular monitor design and fabrication 
The microfluidic transcellular monitor was first conceptualized using the CAD 
software SolidWorks from Dassault Systemes SolidWorks Corp. (Paris, France), after 
which we conducted computational flow studies using the Fluent solver (ANSYS, Inc. 
Concord, MA). The dimensions of the upper and lower microchannels were 200 µm x 100 
µm and 100 µm x 50 µm respectively (width x height). All simulations were solved for a 
single fluid with the Newtonian properties of water and using a structured mesh for the 
device microchannel [127, 160]. The boundary condition at the device inlet was set to 
20 µL/min and 2 µL/min for the average +10 and +1 dyne/cm2 conditions respectively to 
examine the distribution of the WSS in the cell-culture region of the upper microchannel. 
Fabrication of the device started with Ag electrodes patterned onto glass slides using 
metal evaporation deposition [161]. The thin PDMS sheet for the lower microchannel was 
made by spin coating PDMS to 250 µm in height onto an SU-8 patterned silicon wafer. 
The upper microchannel was constructed using standard soft lithography to a patterned 
wafer. An 8 µm pore polycarbonate membrane (Sterlitech Corp, Kent, WA) was then 
treated in a 5% APTES solution at 80C for device assembly prior to device housing [162]. 
The lower microchannel AgCl electrodes were produced using household bleach to soak 
the Ag electrodes for 1 hour at room temperature [163]. The fabricated device was housed 
in a polystyrene box for microfluidic cell culture using syringe pumps (Supplementary Fig. 
S3.1).  
 
Microfluidic endothelial cell culture preparation 
Prior to seeding cells into devices, HAECs, iMAECs, and HUVECs were cultured 
in EGM-2 (Lonza, Basel, Switzerland) and complete endothelial growth medium (DMEM 
with 10% FBS, 1% endothelial cell growth supplement (ECGS), and 1% penicillin and 
streptomycin) respectively. Cell media was replaced every 3 days, with cultures being split 
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at confluence. The device, housing, and tubing were sterilized with 70% ethanol and 
washed with DI-water and PBS (1X, pH 7.4) prior to coating the microchannels with 
fibronectin (50 µg/mL) for 2 hs at 37C. Cells were seeded into the devices at a 
concentration of approximately 1x107 cells/mL. Following a 1 h incubation at 37C, devices 
were connected to Harvard Apparatus (Holliston, MA) PhD Ultra syringe pumps and 
exposed to 20 µL/min (HAECs and HUVECs) or 14 µL/min (iMAECs) while incubating at 
37C. To study the effects of OSS frequency, monolayers were cultured for 24 hours and 
48 hours for HAECs and iMAECs respectively before applying the different shear 
frequencies (Supplementary Fig. S3.3 and S3.4).   
 
TEER measurements 
TEER measurements were taken every 12-24 hrs at 37C using the EVOM2 volt-
ohmmeter (World Precision Instruments, Sarasota, FL). A potential source of error is from 
noise in the TEER measurements, which was reduced by averaging multiple readings for 
each device at every time point, and by taking all measurements at the same temperature 
inside of a cell culture incubator, as TEER can also be affected by temperature fluctuations. 
Measurements were normalized to the mature monolayer value in each device relative to 
when there were no cells in the device (0 h). 
 
Immunostaining of endothelial cells 
Cell fixation was done using 4% paraformaldehyde (PFA) in PBS before 
permeabilizing in 0.1% triton. Samples were blocked with 1% bovine serum albumin (BSA) 
in PBS. Antibody incubation was with anti-β-catenin antibody (ab32572, Abcam, 
Cambridge, UK) and anti-ICAM-1 antibody (322713, BioLegend, San Diego, CA) at 4C 
overnight followed by Cy5 conjugated secondary antibody (ab150075, Abcam). Confocal 
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microscopy imaging of the stained devices was done with a Zeiss LSM 700 microscope 
(Zeiss, Oberkochen, Germany).  
 
Image analysis 
Confocal images of each device were analyzed using the regions of interest (ROI) 
manager in ImageJ. For comparisons of the center and edge regions of the microchannel, 
the microchannel was parsed into 8 sections; the center 4 sections were used to define 
the center ROI, and the outer 4 sections were used to define the edge ROI. For the 
frequency dependency analyses, only the center ROI of the microchannels was compared. 
The individual channels for ICAM and β-catenin were used for ROI comparisons. HUVEC 
areas were calculated using ImageJ ROI manager, where cells were sorted into center 
and edge regions based on the area the cell occupied the most. 
 
Statistical analysis 
Statistical analyses were run in Prism 6 (GraphPad Software Inc, La Jolla, CA) and 
significance was defined as p < 0.05 (*). ANOVA tests were used to compare the TEER 
and immunostaining results of 0X, 0.1X, and 1X frequency cases, and t-tests were used 
for comparisons between the LSS groups and center/edge image analyses. 
 




Figure S3.1. Microfluidic transcellular monitor setup. 
(A) The device during cell culture is enclosed in a polystyrene box with a wire connector interface 
to communicate with an EVOM2 volt-ohmeter. (B) Image of device highlighting the upper 
microchannel (red) and lower microchannel (blue) which are separated by a transparent porous 
membrane. (C) High throughput experimental setup using multi-rack syringe pumps (1) to apply 




Figure S3.2. The effect of the microchannel wall. 
(A) Confocal images of HUVECs that were cultured in a single layer device with the upper 
microchannel geometry and a glass bottom substrate under 0 dyne/cm2 and (B) +10 dyne/cm2 LSS 
conditions. Scale bar is 25 µm. (C) The mean area was compared between cells growing near the 
edge of the channel and cells growing in the center of the channel for 0 dyne/cm2 and (D) +10 
dyne/cm2 normalized to the mean cell area at the edge of the channel (N = 7-8). Plotted as mean 











Figure S3.3. OSS culture timeline for HAECs. 











Figure S3.4. OSS frequency response in iMAECs. 
(A) Contrast image of iMAEC monolayer growing in device with upper (red) and lower (blue) 
microchannels highlighted. Scale bar is 40 µm. (B) Timeline of monolayer growth in devices for 
iMAECs to compare OSS frequency effects on a mature endothelial monolayer. (C) Normalized 
TEER tracking of iMAEC monolayer growth over 72 hrs (N = 4-13). (D) Normalized TEER of iMAEC 
monolayer after 72 hrs of culture under 24 hrs of 0.05 or 0.5 Hz normalized to the LSS case (N = 
3-5). Plotted as mean ± SEM where * is for p < 0.05.  
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CHAPTER 4. PROBING THE IMPACT OF OSCILLATORY 
SHEAR STRESS ON HDL-MIMETIC NANOPARTICLE 
INTERACTIONS WITH THE ENDOTHELIUM 
4.1 ABSTRACT 
 
Translational issues continue to persist in the development of therapies from the 
benchtop to the clinic. In the context of cardiovascular disease (CVD), high-density 
lipoprotein (HDL) therapies have shown promising results in benchtop experiments. 
However, translating these results to the clinic have been mixed at best, causing confusion 
in identifying the role of HDLs in CVD progression and prevention. In this study we 
implement microfluidic technologies to synthesize and screen HDL-mimetic nanoparticles 
engineered to visualize cellular uptake and isolate any protein-based interactions to be 
with apolipoprotein-A1 (apoA1), the most abundant apolipoprotein in the HDL proteome. 
The resulting experiments identified that when above a threshold concentration, our HDL-
mimetic nanoparticles could induce a pro-inflammatory response from human aortic 
endothelial cells cultured under oscillatory shear stress (OSS). However, the same 
response was not observed when the culture conditions used LSS instead of OSS, and 
when the apoA1 receptor scavenger receptor class B type 1 (SR-B1) was inhibited. This 
would indicate that a pro-inflammatory response from the endothelial cells is dependent 




 Natural high-density lipoproteins (HDLs) are 10 nm transporters of fats and nucleic 
acids that have been studied for cardiovascular disease (CVD) therapies due to their 
innate properties that can reduce endothelial inflammation [66, 164]. Identified as the 
primary functional component for HDL, apolipoprotein-A1 (apoA1) is the scaffolding 
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protein of HDL with the purpose of binding lipids and stabilizing the endogenous 
nanoparticle [165, 166]. ApoA1 is also accredited for HDL’s receptor-specific interactions, 
the most common of which is with scavenger receptor class B type 1 (SR-B1); it is the 
primary mode of HDL uptake into a cell and triggering pathways for reverse cholesterol 
transport (RCT) and endothelial nitric oxide (NO) production [93, 167, 168]. With these 
functional properties of HDL in mind, the HDL hypothesis stipulates that increasing the 
concentration of HDL in CVD patients will lower CVD-related incidents; however, mixed 
results in HDL-based therapies suggest an underlying mechanism that can influence HDL 
functionality that has yet to be fully elucidated [27]. To tackle such complicated and 
sensitive mechanistic questions, it becomes necessary to have control over the complex 
composition of HDL; studies focusing on HDL-therapeutics commonly simplify the diverse 
HDL-proteome and lipidome into the combination of a single type of phosphocholine (PC) 
lipid with apoA1 in order to isolate any protein-based interactions with the particle [19, 34, 
37]. Through the simplification of its core components, reconstituted HDLs (rHDLs) may 
be engineered for specific diagnostic or therapeutic applications. The design and 
realization of these engineered HDL-mimetic nanoparticles (eHNPs) may be 
accomplished and accelerated with the application of microfluidic technologies [66]. 
 Microfluidic technologies have enabled the development of various tools with 
which to produce, characterize, and screen nanoparticles like HDL [11]. Microfluidic 
platforms for the single-step synthesis of NPs enable precise control over the mixing 
patterns that encourage the monodisperse self-assembly of NPs [54, 60, 63]. The 
implementation of these microfluidic NP synthesis enables the recovery of a more 
monodisperse batch of NPs with little batch-to-batch variation. Microfluidic platforms may 
also be designed to probe the interactions of nanoparticles in biological settings that more 
accurately mimic physiological conditions when compared to static in vitro culture systems 
[73]. These microphysiological systems, or organ-on-a-chip systems, are designed to 
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culture tissue-specific cells under their respective dynamic culture conditions through the 
use of shear stress, 3D culture environments, or other forms of mechanochemical or 
electrical stimuli [104]. In the case of probing endothelial responses to physiologically 
relevant pathological conditions for CVD, it is critical to consider the magnitude, 
directionality, and frequency of flow [6, 136, 138, 143]. The flow condition credited for the 
initiation of CVD is known as disturbed flow, which involves the flow profile having a bi-
directional pattern over the endothelium at a frequency of about 1 Hz in humans [136]. 
This oscillatory shear stress (OSS) enhances the inflammatory response of the 
endothelium, triggering its enhanced permeabilization and its upregulation of adhesion 
molecules like intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion 
molecule-1 (VCAM-1) relative to when the endothelium is cultured under laminar shear 
stress (LSS) conditions [136, 138, 139]. These responses may be characterized through 
immunostaining of the monolayer and the transendothelial electrical resistance (TEER), 
the real-time resistance measurement across the endothelial monolayer that correlates 
with the permeability of the monolayer [73, 136]. However, due to the technical challenges 
that need to be overcome in order to implement microfluidic platforms for both NP research 
and biomimetic platforms, there is a lack in the number of studies that utilize microfluidics 
to synthesize and screen NPs despite the many advantages microfluidics may provide.  
In order to uncover portions of the complex interactions between HDL and the 
inflamed endothelium, it is necessary to monitor the response of the endothelium in a 
dynamic microenvironment with compositionally homogenous HDLs (Fig. 4.1A). With the 
purpose of isolating the interactions between HDL and the inflamed endothelium to be 
apoA1-dependent, we implemented our microvortex propagation mixer (µVPM) to 
synthesize eHNPs for which we controlled the NP composition (Fig. 4.1B). We then 
probed the permeability and adhesion molecule expression levels of the endothelium to 
our eHNPs under both LSS and OSS conditions in a microfluidic transcellular monitor 
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(µTM) to discover if there was a flow-dependent endothelial response to our apoA1-based 
eHNPs (Fig. 4.1C). 
 
Figure 4.1. Detecting flow-dependent interactions of HDL with the endothelium. 
(A) Oscillatory flow conditions relevant to CVD in humans is achieved using biomimetic 
microphysiological systems in order to study HDL interactions with the endothelium. (B) Engineered 
HDL-mimetic nanoparticles (eHNPs) with microfluidics enables control over composition. (C) The 
microfluidic transcellular monitor allows for both real-time and endpoint measurements of the 
monolayer through TEER and confocal analysis. (D) TEER, (E) ICAM, and (F) eHNP uptake LSS-
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normalized measurements in response to LSS or OSS with eHNPs at a concentration of 25 µg/mL 
(N = 3-4). *, **, and **** are for p < 0.05, 0.01, and 0.0001 respectively. 
 
   
4.3 RESULTS AND DISCUSSION 
 
Endothelial cells respond to eHNPs depending on the oscillatory flow condition. 
 Upon conditioning with LSS, or the non-oscillating shear stress (0 Hz), endothelial 
cells (ECs) showed no detectable changes in monolayer permeability or ICAM expression 
when stimulated with eHNPs (Fig. 4.1D and E). However, ECs stimulated with both OSS 
at 1 Hz and eHNPs displayed a significantly different response to when ECs were 
stimulated with OSS at 1 Hz alone; the endothelial permeability and ICAM expression 
were both amplified in the presence of both OSS and eHNPs (Fig. 4.1D and E). Despite 
the significant differences in responses to eHNPs when under 0 or 1 Hz flows, there was 
no significant difference in the fluorescent signal of eHNPs in ECs (Fig. 4.1F). This would 
indicate that the rate of endothelial eHNP uptake was the same between 0 and 1 Hz 
stimulation conditions, and that such a rate is not influenced by the oscillatory condition of 
the shear stress. However, from these initial results we found that interactions between 
the endothelium and the eHNPs are modulated with the flow conditions with which the 
ECs are stimulated; eHNPs appear to stimulate a non- or pro-inflammatory response from 
ECs depending on stimulation with LSS or OSS flow. While it is not unheard of for natural 
HDLs to be dysfunctional under certain oxidative conditions [33], this finding connects the 
endothelial-HDL interactions with the endothelial flow condition. To gain a better 
understanding over the mechanisms of this response, it is imperative to identify other 
parameters that may change the ICAM expression and endothelial monolayer permeability. 
One such parameter is the eHNP concentration. 
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Figure 4.2. eHNP concentration dependent analysis with LSS. 
(A) TEER, (B) ICAM, and (C) eHNP uptake LSS-normalzied measurements (0 Hz & 0 µg/mL) under 
LSS conditions (N = 3-4). (D) Confocal images of the endothelium in response to varying eHNP 
concentrations (scale bar is 40 µm). ** is for p < 0.01. 
 
The endothelial response to eHNPs is conditionally concentration-dependent. 
 When increasing the concentration of eHNPs stimulating ECs from 1 to 25 µg/mL 
under 0 Hz flow, there were no significant differences in either the TEER or ICAM intensity 
measurements (Fig. 4.2A and B). With the exception of a 2-fold increase in the fluorescent 
intensity measurements for eHNP uptake (Fig. 4.2C), the monolayer showed no significant 
differences in the fluorescent channels when increasing the eHNP concentration under 0 
Hz flow (Fig. 4.2D). Upon changing the condition to a 1 Hz OSS flow however, varying the 
concentration of eHNPs from 1 and 25 µg/mL had significant impacts on both the TEER 
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and ICAM expression measurements (Fig. 4.3A and B). With the same 2-fold increase in 
eHNP uptake (Fig. 4.3C) as the 0 Hz flow case, confocal analysis of the endothelial 
monolayer shows a clear distinction in the 25 µg/mL eHNP group from both the 0 and 1 
µg/mL groups under 1 Hz flow (Fig. 4.3D).  
 
Figure 4.3. eHNP concentration dependent analysis with OSS. 
(A) TEER, (B) ICAM, and (C) eHNP uptake LSS-normalized measurements (0 Hz and 0 µg/mL) 
under OSS conditions (N = 3-4). (D) Confocal images of the endothelium in response to varying 
eHNP concentrations (scale bar is 40 µm). *, **, and *** are for p < 0.05, 0.01, and 0.001 
respectively. 
 
This conditional dependency on eHNP concentration presents a threshold at which 
the concentration of eHNPs may trigger a pro-inflammatory phenotype depending on the 
oscillatory flow condition. However, it remains unclear if there is another threshold at which 
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there is an eHNP concentration that could be anti-inflammatory under OSS conditions. 
The rationale for such a stipulation stems from our previous study that presented the 
biphasic response of ECs to varying eHNP concentrations, for which a certain range would 
stimulate angiogenic sprouting while another range would inhibit angiogenic sprouting 
[107]. The significance of our finding is still impactful despite this possibility; the differences 
between 0 and 1 Hz flow cases with regards to the endothelial response to varying eHNP 
concentrations exemplifies a flow-dependent and concentration-dependent response that 
requires meeting multiple criteria: the oscillatory flow frequency [136], and the eHNP 
concentration. Determining the mode through which this flow- and concentration-
dependent interaction between eHNPs and ECs is mediated necessitates exploring the 
role of SR-B1, the primary receptor for apoA1.  
 
The amplified endothelial response to OSS and eHNPs is absent without SR-B1.  
 Should the primary interaction between our eHNPs and the ECs be mediated 
through apoA1, then the inhibition of its primary receptor, SR-B1, should temper the 
endothelial response to the eHNPs under 1 Hz OSS flow. The agent block lipid transport-
1 (BLT-1) has been routinely used to block SR-B1 in studies involving cellular uptake of 
HDL and the induction of RCT [169, 170]. Inhibition of SR-B1 with BLT-1 in our µTM 
platform resulted in the absence of the amplified effects of eHNP and 1 Hz OSS flow, as 
reflected in both the TEER and ICAM measurements (Fig. 4.4A and B). The uptake of 
eHNPs was halved with the endothelial treatment of BLT-1 for both 0 Hz LSS and 1 Hz 
OSS flow conditions (Fig. 4.4C). The non-significant differences in eHNP uptake between 
0 and 1 Hz flows are consistent with the uptake of eHNPs when BLT-1 was not used (Fig. 
4.1F), which showcases that the uptake of the eHNPs with or without BLT-1 does not 
depend on the oscillatory flow condition. Confocal analysis of the endothelial monolayer 
also shows decreased uptake in both 0 and 1 Hz flows without affecting the pro-
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inflammatory stimulation of the 1 Hz OSS flow, which retained a comparable level of ICAM 
stimulation (~1.5X that of the 0 Hz LSS cases) to when ECs were conditioned under 1 Hz 
OSS without BLT-1 (Fig. 4.4D and E). This result is indicative of the endothelial response 
to eHNPs at 25 µg/mL with the 1 Hz OSS condition to be dependent on the availability of 
SR-B1. The significance of this conclusion is in the identification of multiple roles that SR-
B1 may have when interacting with apoA1; while it has been known that interactions 
between SR-B1 and apoA1 could promote anti-inflammatory processes such as the 
production of endothelial NO and RCT, a pro-inflammatory response resulted from this 
interaction only when OSS was present.  
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Figure 4.4. Endothelial response to eHNPs when SR-B1 is blocked. 
(A) TEER, (B) ICAM, and (C) eHNP uptake LSS-normalized measurements under LSS or OSS 
conditions when BLT-1 is used (N = 3-4). TEER and ICAM values were normalized to LSS without 
eHNPs (0 µg/mL), whereas eHNP uptake was normalized to LSS with eHNPs (1 µg/mL). (D) 
Confocal images of the endothelium in response to BLT-1 pretreatment (scale bar is 40 µm). (E) 
Zoomed confocal images comparing eHNP localization near nucleus under LSS and (F) OSS flow 





This study applied a µTM platform to track the interactions of the endothelium with 
microfluidically synthesized eHNP-A1, isolating the mechanism of protein-based 
interactions to be through apoA1. We identified a complex interaction between ECs and 
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eHNP-A1, which was dependent on several key factors: the flow profile of the 
microenvironment, the concentration of eHNP-A1, and the availability of SR-B1. Under the 
influence of LSS flow, eHNPs did not elicit a response from the endothelium over the range 
of concentrations from 0-25 µg/mL. Unlike with the LSS case, eHNPs did elicit a pro-
inflammatory phenotype in ECs stimulated with an OSS flow. However, this pro-
inflammatory response was only observed with the higher eHNP-A1 concentration (25 
µg/mL). In order to determine if apoA1 was playing a key role in this inflammatory 
response, the apoA1 receptor SR-B1 was inhibited with BLT-1. The inhibition of SR-B1 
still resulted in a proinflammatory response from the endothelium exposed to both OSS 
and eHNP-A1, however the degree of inflammation closely matched that of the OSS only 
case. The significance of these findings stems back to the original HDL hypothesis, which 
stipulates that increased blood concentrations of HDL could lead to lower CVD-related 
events. With much confusion surrounding clinical trials involving HDL-related therapies 
and their mixed results, the findings from this study help to elucidate some of this confusion. 
An apoA1-mediated pro-inflammatory EC response was found under OSS conditions, but 
was not found under LSS conditions. This was accomplished through the combination of 
our µVPM and µTM, which serve to synthesize and monitor our eHNPs under biomimetic 
conditions for CVD initiation. With these findings, future work that may be conducted to 
further expand our study could probe different parameters that we have yet to test. These 
parameters may include other compositions for eHNPs, a wider range of eHNP 
concentrations, and the use of gene sequencing or proteomics to visualize the endothelial 




Materials and chemicals 
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The reagent (3-aminopropyl)triethoxysilane (APTES) was purchased from Sigma-
Aldrich Co. LLC. (St. Louis, MO). Polydimethylsiloxane (PDMS) was purchased as Sylgard 
184 from Dow Corning (Midland, MI). The photoresist SU-8 and its developer were 
purchased from MicroChem Corp (Westborough, MA). HAECs were purchased from 
ATCC (Manassas, VA). 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(Rhodamine-DMPE) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). ApoA1 
from human plasma and BLT-1 were purchased from Sigma-Aldrich Co. LLC. (St. Louis, 
MO). 
 
Microfluidic transcellular monitor fabrication 
The dimensions of the upper and lower microchannels were 200 µm x 100 µm and 
100 µm x 50 µm respectively (width x height) [136]. Fabrication of the device started with 
Ag electrodes patterned onto glass slides using metal evaporation deposition [161]. The 
thin PDMS sheet for the lower microchannel was made by spin coating PDMS to 250 µm 
in height onto an SU-8 patterned silicon wafer. The upper microchannel was constructed 
using standard soft lithography to a patterned wafer. An 8 µm pore polycarbonate 
membrane (Sterlitech Corp, Kent, WA) was then treated in a 5% APTES solution at 80C 
for device assembly prior to device housing [162]. The lower microchannel AgCl 
electrodes were produced using household bleach to soak the Ag electrodes for 1 hour at 
room temperature [163]. The fabricated device was housed in a polystyrene box for 
microfluidic cell culture using syringe pumps.  
 
eHNP synthesis 
The NP precursor solutions included a lipid solution that was composed of DMPC 
and Rhodamine-DMPE with a concentration of 2.75 mg/mL in 200 proof ethanol, and a 
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protein solution that had apoA1 with a concentration of 0.2 mg/mL in PBS (1X, pH 7.4). 
Syringe pumps from Harvard Apparatus (Holliston, MA) were used to pump the solutions 
into the µVPM as previously described, from which the mixed solution was collected and 
then triple washed with PBS using a 30,000 MW centrifugal filter from EMD Millipore 
Corporation (Darmstadt, Germany) at a speed of 3900 rpm for 20 minutes [66]. The size 
distribution of the final washed sample was measured with a Zetasizer Nano ZS from 
Malvern Instruments (Worcestershire, United Kingdom).  
 
Microfluidic endothelial cell culture  
Prior to seeding cells into devices, HAECs were cultured in EGM-2 (Lonza, Basel, 
Switzerland) with 0.1% gelatin. Cell media was replaced every 3 days, with cultures being 
split at confluence. The device, housing, and tubing were sterilized with 70% ethanol and 
washed with DI-water and PBS (1X, pH 7.4) prior to coating the microchannels with 
fibronectin (50 µg/mL) for 2 hs at 37C. Cells were seeded into the devices at a 
concentration of approximately 1x107 cells/mL. Following a 1 h incubation at 37C, devices 
were connected to Harvard Apparatus (Holliston, MA) PhD Ultra syringe pumps and 
exposed to 20 µL/min while incubating at 37C. Monolayers were allowed to culture for at 
least 24 h in order to mature before the addition of eHNPs or OSS [136].  For the SR-B1 
inhibition studies, BLT-1 was incubated with the ECs at a concentration of 150 µM for 1 h 
at 37ºC before rinsing and adding eHNPs to the culture media.  
 
TEER measurements 
TEER measurements were taken every 12-24 hrs at 37C using the EVOM2 volt-
ohmmeter (World Precision Instruments, Sarasota, FL). A potential source of error is from 
noise in the TEER measurements, which was reduced by averaging multiple readings for 
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each device at every time point, and by taking all measurements at the same temperature 
inside of a cell culture incubator, as TEER can also be affected by temperature fluctuations. 
Measurements were normalized to the mature monolayer value developed under LSS 
relative to when there were no cells in the device (0 h). 
 
Immunostaining of endothelial cells 
Cell fixation was done using 4% paraformaldehyde (PFA) in PBS before 
permeabilizing in 0.1% triton. Samples were blocked with 1% bovine serum albumin (BSA) 
in PBS. Antibody incubation was with anti-β-catenin antibody (ab32572, Abcam, 
Cambridge, UK) and anti-ICAM-1 antibody (322713, BioLegend, San Diego, CA) or anti-
VCAM-1 antibody (305806, BioLegend, San Diego, CA) at 4C overnight followed by an 
Alexa Fluor 647 conjugated secondary antibody (ab150075, Abcam). Confocal 
microscopy imaging of the stained devices was done at 10X with a Zeiss LSM 700 
microscope (Zeiss, Oberkochen, Germany).  
 
Image analysis 
Confocal images of each device were analyzed using the regions of interest (ROI) 
manager in ImageJ. Only the center ROI of the microchannels was compared between 
cases, as the center of the microchannel is the region where the endothelium experiences 
the desired shear stress [136]. The individual channels for eHNPs, VCAM/ICAM and β-
catenin were used for ROI comparisons. Cell angles were calculated using ImageJ, and 
were defined as the angle between the vertical axis of the channel and the long axis of 





Statistical analyses were run in Prism 7 (GraphPad Software Inc, La Jolla, CA) and 
significance was defined as p < 0.05 (*). ANOVA tests were used for multiple comparisons. 
 
 
4.6 SUPPLEMENTARY INFORMATION 
 
 
Figure S4.1. HAEC culture using collagen 1. 
(A) Monolayer development was tracked with TEER over 72 hours (N = 3). (B) TEER LSS-
normalized measurements under LSS or OSS conditions after 72 hours of LSS culture (N = 3). (C) 
ICAM and (D) VCAM localization to the center region of the HAEC monolayer (N = 8). (E) Confocal 
images of the LSS and (F) OSS stimulated monolayer stained for ICAM and (G) VCAM (scale bar 





Figure S4.2. Orientation of HAECs under LSS or OSS. 
(A) HAEC orientation relative to the vertical axis of the microchannel when cultured on fibronectin 
and treated with LSS or (B) OSS. (C) HAEC orientation when cultured on collagen 1 and treated 
with LSS or (D) OSS.   
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CHAPTER 5. CONCLUSIONS 
5.1 CONCLUDING REMARKS 
 
The vision for this work was centered around exploring the microfluidic methods in 
the engineering and screening of multifunctional nanomedicines. The studies conducted 
in helping to realize this vision reflect accomplishments in the detection of functional 
differences between HDL-mimetic NPs using microfluidics [66], the development of a 
biomimetic pathological microenvironment to study CVD-mediated endothelial responses 
[136], and the screening of interactions between HDL-mimetic NPs and endothelial cells 
cultured in the CVD-mimetic pathological microenvironment. These studies first required 
the development of the µVPM platform that could continuously produce the necessary 
amount of NPs while maintaining NP monodispersity through efficient mixing of the 
nanoparticle precursors. The µVPM was implemented alongside computational MD 
simulations and a microengineered vascular system to functionally compare eHNPs made 
from either natural apoA1 or a synthetic apoA1-mimetic peptide known as r4F, which 
showed that eHNPs made from natural apoA1 were more stable and could better trigger 
SR-B1 dependent endothelial responses. The need to develop the µTM stemmed from 
the desire to study the endothelium under an oscillatory flow condition with real-time 
permeability measurements and end-point confocal analysis. This platform was 
implemented to both probe how the endothelium would respond to different oscillatory flow 
frequencies and to the addition of our eHNPs synthesized with our µVPM. The resulting 
conclusions from these experiments that were enabled through microfluidics contribute to 
the understanding of how various microfluidic platforms may be implemented together for 
the translational process of experimental therapeutics. As a disclaimer, it is important to 
point out that the terms OSS and LSS were adopted for consistency with the terms used 
in the CVD community. However, flow in microfluidic channels is laminar. In our case, the 
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“LSS” flow profile was a unidirectional steady laminar flow and the “OSS” flow profile was 
a laminar flow that changed direction every half second.  
 
5.2 CURRENT CHALLENGES AND FUTURE WORK 
 
Currently, the initial challenge in designing and implementing microfluidic platforms 
is in the limited access to cleanroom facilities and the tools required to fabricate the molds 
for microfluidic channels. While some work has been done by various companies to make 
such tools more accessible without the need for a cleanroom, there still exists a 
substantially high investment that is required to enter the specialized field of microfluidics. 
This thesis aims to assist in standardizing the workflow for the development and the 
implementation of microfluidic platforms by providing a perspective into designing and 
applying microfluidic platforms through the context of both the synthesis of HDL-mimetic 
nanoparticles and the mimicry of a CVD-affected endothelial microenvironment. It should 
be noted that there is a key difference between the standardization of workflow and the 
standardization of design; the standardization of workflow identifies checkpoints in 
platform development that are to be kept constant, whereas the standardization of design 
identifies key parameters or characteristics of the engineered platform that need to be kept 
constant. Other challenges include the technical difficulty in assembling complex multi-
layer platforms, as well as the determination of key design parameters during the 
conceptualization of new microfluidic platforms. The studies to follow-up the results from 
chapters 2-4 have been outlined below. 
 
ApoA1-mimetic peptide potential 
 The results of chapter 2 showed that for a given composition of HDL-mimetic 
nanoparticles, apoA1-based nanoparticles were more stable and effective in soliciting 
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cellular responses than r4F-based nanoparticles. The work that should immediately follow 
this study should explore additional HDL-mimetic compositions. It should be well noted 
that the comparisons between apoA1 and r4F were done in the context of a single 
simplified composition used for both diagnostic and therapeutic applications. With this 
study using the simplest form of reconstituted HDL to compare apoA1 to r4F, the 
modification of the nanoparticle formulation to compare their respective functionalities 
would provide further insight into ways nanoparticle formulation may modulate the degree 
to which r4F and apoA1 differ. For instance, modifying the composition to incorporate 
polyethylene glycol (PEG) to the surface of the nanoparticles may improve the stability 
[171], and overall performance, of the r4F-based nanoparticles while maintaining the 
stable properties of apoA1-based nanoparticles. In addition, applying this same 
comparison method with additional well-used apoA1-mimetic peptides, such as ETC-642 
[172], could be insightful to how other apoA1-mimetic peptides may trigger known apoA1 
pathways. Having multiple apoA1-mimetic peptides to compare may also enable studies 
to understanding the intricacies of how apoA1 functions. 
 
Balancing the complexity and robustness of the µTM 
 The microfluidic transcellular monitor (µTM) is a robust platform that can monitor 
the permeability of an endothelial monolayer, which was shown in a simplified cellular 
microenvironment with endothelial cells. Biology is much more complicated; striking a 
balance between complexity and usability for microphysiological systems is a major 
challenge. The immediate work to follow the µTM would be to try and find this balance by 
including additional peripheral cell types, such as fibroblasts or vascular smooth muscle 
cells, to shift the endothelial microenvironment to be more physiologically relevant. This 
could be done by culturing these peripheral cells under static conditions on the underside 
of the porous membrane to monitor how the peripheral cells may interact with the 
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endothelium that is under flow. In addition, several groups have begun to shift to 
impedance-based measurements for endothelial permeability due to its robustness in fine-
tuning measurements across multiple frequencies [75]. Incorporating platinum or gold 
electrodes in place of the silver chloride electrodes may improve the accuracy of the TEER 
measurements taken with the µTM. 
 
Exploring the pro-inflammatory effects of eHNP-A1 
Since it has been reported that natural HDL functionality can be modulated through 
its oxidation by reactive oxygen species (ROS) [33], measurements of the ROS levels 
generated in the µTM during OSS and LSS conditioning of the endothelium could provide 
insightful data to the endothelial microenvironment affecting eHNP-A1. Should there be a 
significant difference between the levels of ROS generated between LSS and OSS 
conditions, an antioxidant should be then used to see if there is any change in the 
response of the endothelium to eHNP-A1 under OSS and LSS conditions. In addition, 
comparing this response to purified natural HDL and purified oxidized HDL may provide 
further insights into the contributions of oxidation. This study should take into account the 
lot from which the HDLs are purified due to the compositional variation of natural HDLs. 
Therefore, multiple lots must be used across purified HDL and purified oxidized HDL 
during comparisons. 
 
Long-term vision  
Long-term future directions for the studies presented in this work may include the 
development of an eHNP library to track how the endothelium may respond to various 
compositions of eHNPs, and to comparing the responses between human and animal-
derived endothelial cells in order to determine the sensitivity of these cells to physiological 
conditions specific to their species. Natural HDLs have a complex lipidome and proteome. 
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It is known that various lipids and proteins like sphingosine-1-phosphate (S1P), 
cholesterylester transfer protein (CETP), and paraoxonase-1 (PON1) can be a part of 
HDL’s composition while contributing to and modulating HDL’s functionality [33]. The 
difficulty in studying these processes from human purified HDLs is in the heterogeneity of 
HDL’s composition; however, with our compositional control over the eHNP formulations, 
microfluidic platforms are well-positioned to tackling this challenging question. A library 
that can track all these responses would be an incredibly powerful tool to multiple research 
communities, as it will provide a way to organize and relate the functional contributions of 
each component within a controlled microenvironment.  
Microfluidic platforms mimicking organ-specific microenvironments use 
parameters most physiologically relevant to that of humans in order to study cellular 
responses in human-like conditions. However, many of these studies may end up being 
paired with animal models to validate how the microfluidic model responds to certain 
external stimuli. An important factor to keep in mind when conducting such validation 
studies is that the motivation of developing microfluidic human-like in vitro models 
originates from the inherent differences between animal models and humans. Therefore, 
it would be imperative to compare how animal and human cells respond to their respective 
physiological microenvironments within a microfluidic platform before comparing the 
results obtained from the microfluidic platform to results obtained from an animal model. 
In the case of CVD and the endothelium, parameters over which to study these differences 
would include flow frequency and shear stress between mouse and human aortic 
endothelial cells. Depending on the availability of aortic endothelial cells from various 
species, the study could also be extended to probing therapies that failed in clinical studies 
that also succeeded in various animal trials. Such comparisons would yield highly 
impactful results that would help to uncover explanations to the differences between 
animal and human models. 
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This protocol describes the process flow for the assembly and use of the µTM. The 
µTM is a microfluidic tool for studying the barrier function of cells in response to changes 
in mechanochemical environments that can be changed through the flow conditions and 
media composition. This device combines the recording of TEER, fluorescent microscopy, 
and media sampling for the collection of data. 
 
The basic points to making and using this device are as follows: 
 
1. Fabrication of the electrodes and silicon wafers 
2. Softlithography of PDMS to the silicon wafers 
3. Assembly of the device through plasma cleaning 
4. Assembly of the device housing 
5. Prep needed for cell seeding 
6. Seeding cells 
7. Initiating culture under flow 
 
A.2. ELECTRODE FABRICATION 
 
Materials and equipment by process flow: 
1. Cut and clean glass wafers 
1. Large glass slide (Ted Pella 260233 6”x4.5”) 
2. Glass cutter (McMaster-Carr 3867A11) 
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2. Pattern glass wafers with photoresist 
1. Teflon dish for 100mm wafers 
2. Large glass dish for wafers larger than 100mm 
3. Transparency mask for electrode pattern 
4. Timer 
5. Wafer tweezers 
6. Provided by IEN 
1. Buffered oxide etch (BOE) WARNING: CONTAINS HF 
2. Futurrex NR9-1500py positive photoresist 
3. Futurrex RD6 Developer 
4. DI Water 
5. Texwipes 
6. Oven 
7. Hot Plate 
8. Nitrogen gun 
9. Aluminum foil or parafilm 
10. Spin Coater (BLE or SCS) 
3. Deposit metal onto patterned glass wafers (material/equipment provided by IEN) 
1. Vision RIE 2 
2. Titanium 
3. Silver 
4. CHA E-Beam Evaporator 2 
4. Metal liftoff 
1. Large glass dish for 100mm wafer 
2. Acetone 
3. Waste container (empty acetone bottle) 
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4. DI water 
5. Glass cutter 
 
Cutting glass slides 
Cut the glass slides as per the following drawing - these cut glass slides will now 
be referred to as wafers: 
 
Figure A.1. Cutting diagram for glass slide. 
 
 
Patterning the glass 
1. Pour BOE (Located in "A" cabinet) into a teflon dish, and submerge one glass 
wafer at a time into the dish for 1 minute each.  
2. After soaking the glass wafer in BOE for 1 minute, thoroughly rinse the glass 
slide under cold running DI water. 
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3. Use the nitrogen gun to blow off the water while using a paper towel to absorb 
any water that run to the edges of the glass.  
a. Always start the nitrogen gun at the center of the wafer and then move 
away from the center. Do not move the nitrogen gun back to the center 
while on as it risks water being blown back onto the wafer. Do this step as 
carefully as possible. 
4. Place the cleaned wafer into a 100ºC oven for a minimum of 15 minutes as a 
dehydration bake.  
5. Set one hotplate to 100ºC and another for 150ºC and label that they are in use. 
6. While the wafers are baking, set the spin coater for a 30 second spin at 2000rpm 
with a 1000rpm/s ramp. 
7. Spin the NR9-1500py photoresist onto the wafers. 
a. if using the BLE spinner, use a 6 in wafer chuck and seal the chuck with 
aluminum foil (or parafilm). After sealing the foil to the chuck, poke holes 
at the center ridges of the chuck so that the vacuum will have a tight seal 
with the glass wafer. 
8. Place the coated wafers onto the 150ºC hotplate for 7 minutes as a softbake. 
9. Expose the wafers with a mask aligner holding the electrode mask using 
780mJ/cm2. 
10. Place the newly exposed wafers onto the 100ºC hotplate and bake for 17 
minutes as a post exposure bake. 
11. In the hood, fill a glass dish half way with RD6 and set a timer for 12 seconds. 
12. Have gentle running DI water ready for this next step - Immerse the baked 
glass wafers into the developer for 11.5 seconds and then IMMEDIATELY place 
the wafer under the running DI water to wash off the developer (do this for 
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roughly 1 minute) - the development is extremely time sensitive, have the glass 
wafer under running DI water at the 12 second mark. 
13. Dry the wafers with a nitrogen gun. 
 
Metal deposition 
1. Use an RIE (ex. the Vision RIE 2) to run a descum process on the wafers: 
a. Process Pressure and RF setpoint - 250 torr. 
b. Stabilization time - 45 seconds. 
c. Gases: Argon-5 Oxygen-50. 
2. After running the descum, deposit metal onto the wafer surface using a metal 
evaporator: 
a. a 50nm (0.5kÅ) layer of Ti with a deposition rate of 1Å/s. 
b. a 500nm (5kÅ) layer of Ag with a deposition rate of 3Å/s. 
 
Metal liftoff 
1. Fill a glass dish with acetone and another dish with DI water. 
2. Immerse silver coated wafer in the acetone and use wafer tweezers to rock the 
wafer up and down until the silver lifts off the surface. 
3. Remove the wafer from the acetone and place in the DI water. 
a. If the acetone dish is full of detached silver, dispose of solvent waste into 
a labeled waste container and refill with new acetone. 
4. Use the nitrogen gun to remove any water or detached silver from the wafer. 
5. Cut out each individual device using the glass cutter. 
 
 
A.3. µTM ASSEMBLY 
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Materials and equipment: 
1. PDMS (Sylgard 184 Elastomer Kit) 
2. Glass electrodes 
3. Silicon wafer molds (Upper and Lower channel molds) 
4. Polycarbonate membrane - 8µm pore (Sterlitech PCTB8025100) 
5.  (3-Aminopropyl)triethoxysilane a.k.a. APTES  5% solution in DI water (Sigma 
440140) 
6. Biopsy punch 1mm 
7. Biopsy punch 4mm 
8. Tygon silicon tubing (Cole Parmer 95702-00) 
9. PE60 tubing (BD Intramedic 427415) 
10. Clear plastic container (Ted Pella 139-75) 
11. 100mm petri dish filled with cured PDMS 
12. 100mm petri dish filled with kimwipes 
13. 60mm petri dish 
14. Benchtop microscope 
15. Scissors 
16. Precision knife 
17. Tweezers 
18. Hot plate (80ºC) 
19. Plasma cleaner 
20. Oven (80ºC) 
21. Microscope glass slide  
22. Paper-based masking tape – for clamping 
23. Scotch magic tape (3M 810) – for cleaning 
24. Soldering Iron 
 95 
25. Solder 
26. Silver wire (A-M systems 783000) 
27. Socket connecter (Digikey ED10864-ND) 
28. Shrink tubing (McMaster-Carr 7856K72) 
29. Sealant glazing rope (McMaster-Carr 1049A31) 
30. Silver epoxy (MG Chemicals 8330S-21G) 
 
Procedure: 
1. Cure PDMS to the upper channel mold so that the height is between 5 and 
10mm from the surface of the silicon wafer. 
2. Spin PDMS onto the lower channel mold using the following recipe: 
1. Step 1: 100rpm at 50rpm/s for 10 seconds. 
2. Step 2: 250rpm at 50rpm/s for 93 seconds. 
3. Cure on hotplate at 100ºC for 5 minutes -or- 80ºC for 20 minutes. 
3. Plasma bond a lower channel PDMS device to the glass electrode 
1. Clean the glass electrode slide 3 times with tape and leave tape on after 
3rd cleaning. 
2. Place a lower channel section cutout channel side UP onto the PDMS 
petri dish (make sure that the cutout lower channel section is not large 
enough to cover the electrode pads). 
3. Punch the 4mm holes all the way through the 4mm hole markers and 
remove punches using tweezers. 
4. Place lower channel flat onto a clean glass slide channel side DOWN. 
5. Clean the backside of the lower channel with tape 3 times. 
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6. Remove the lower channel from the glass slide and place it channel side 
DOWN into the plasma cleaner with the glass electrode (make sure to 
remove all tape from devices). 
7. Plasma clean for 1 minute on the RF Hi setting. 
8. Making sure to align the 4mm holes with the 4mm electrodes, bond the 
glass slide to the lower channel PDMS (handle glass electrode instead of 
lower channel while doing this). 
9. Place a paper-taped glass slide on top of the device (tape side to the 
PDMS) and clamp with a binder clip before placing in an 80ºC oven for at 
least 20 minutes. 
4. Cut and treat polycarbonate membranes for bonding 
1. Place glass vial APTES solution onto a 80ºC hot plate - Loosen lid to 
avoid pressure buildup. 
2. Roughly cut out 5mmx10mm sections of the polycarbonate membrane. 
3. Place the membrane cutouts into a 60mm dish (without the lid). 
4. Plasma clean membrane cutouts for 1 min. 
5. Place the plasma cleaned membrane cutouts into the warmed APTES 
solution for at least 20 minutes. 
6. Dry the membrane cutouts on kimwipes in a petri dish - Separate 
overlapping/folded membranes before fully dry. 
5. Assembling PDMS components together 
1. Take the lower channel assembly out of the oven and remove the clamp 
taped glass slide. 
2. Clean the lower channel assembly with tape 3 times. 
i. IMPORTANT: check to make sure that the PDMS is firmly bonded 
to the glass slide, if not then dispose of the assembly immediately.  
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3. Cut out and punch inlet/outlet holes for the upper channel using a 1mm 
biopsy punch (punch into the PDMS from the channel side). 
4. Clean the upper channel, channel side UP, with tape 3 times. 
5. Plasma clean the lower channel assembly and upper channel; both 
should be channel side UP. 
6. Immediately apply a dried membrane cutout onto the lower channel, 
making sure to center and cover the majority of the long straight section 
7. Bring lower channel assembly and upper channel to the microscope, and 
bond the two together using the following procedure: 
i. Clamp down the lower channel assembly with the microscope 
sample clips. 
ii. Adjust the microscope lens so it is focusing slightly above the 
lower channel surface. 
iii. Hold the upper channel PDMS above the lower channel assembly. 
iv. Carefully align the upper and lower channels so that the lower 
channel is centered between the upper channel.  
v. Gently press the two sections together and clamp them together 
with a taped glass slide and binder clip. 
vi. Leave the assembly in the oven for 15 minutes. 
6. Prepare the silver epoxy (1:1 ratio) and dip one end of a 2" length of silver wire 
into the epoxy.  
7. Place the epoxy coated end of the wire on the electrode pad and push down 
using tweezers to insure adequate adhesion (1 wire per pad). 
8. Allow the silver epoxy to cure in an 80˚C oven for 24 hours. 
9. Apply heat shrink to the wires, leaving 1cm at the un-adhered end of the wire 
exposed. 
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10. Drill four 7/64’’ holes (marked red) into the back of a box using the diagram / 




Figure A.2. Location of drilled holes for wires of µTM. 
 
11. Clean out the machined box and place the soldered chip into the box with the 4 
wires coming out of the holes.  
12. Cut out small pieces of the sealant glazing rope.  
1. Use one piece to secure the device to the bottom of the container - 
Smaller pieces are better imaging. 
2. Using tweezers, surround the wires where they come out of the holes and 




Figure A.3. Location of sealant for µTM. 
 
13. Pour roughly 10 grams of PDMS around the device to fix it in place, making sure 
to pour over the wires. The silver epoxy and wires must be completely 
submerged in PDMS. Bake in the 80ºC oven to cure. 
14. Solder the connectors to the end of each exposed wire and insulate the solder 
joint with heat shrink tubing. 
15. Dip the end of the connectors in silver solder and insert them into a strip of four 
socket connectors. Use as little epoxy as possible to avoid shorts. Allow 
epoxy to cure in an 80ºC oven for 24 hours. 
16. Mark the inlets/outlets on the lid of the box, and drill a hole into the lid for each 
inlet/outlet using the 7/64’’ bit (remove the lid from the device before doing this, 




Figure A.4. Final device ready for cell culture. 
 
17. Prepare 3 sets of tygon tubing at least 10cm long with 1cm long PE60 tubing 
adapters.  
1. DO NOT autoclave the PE60 tubing adapters. To sterilize, leave the 
tubing sets under UV overnight.  
2. Do not place the device in UV or the autoclave because the 
polycarbonate membrane is not autoclavable and the silver electrodes 
are sensitive UV light. Sterilization will be done with ethanol. 
 
 
A.4. CELL CULTURE 
 
Materials and equipment: 
1. Assembled device with tygon/PE60 tubing sets  
2. Syringe pump (Harvard apparatus PhD Ultra) 
3. Tygon silicon tubing (Cole Parmer 95702-00) 
4. PE60 tubing (BD Intramedic 427415) 
5. 3mL syringes (BD 309657) 
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6. 30mL syringes (BD 302832) 
7. 18G needles (BD 305180) 
8. 70% ethanol 
9. PBS 1X 
10. Fibronectin (50µg/mL) 
11. Cell sample (1 confluent T25 flask) and cell growth media 
12. Bleach (to chlorinate electrodes) 
13. 1-10µL pipette and tips 
14. 20-200µL pipette and tips 





1. Add a 3µL droplet of bleach to the lower channel inlet/outlet (the outer 
inlet/outlet) and let set for 1hr at room temperature  
1. Make sure the entire electrode is covered 
2. Add a 3µL droplet of ethanol to the upper channel inlet/outlet (the inner 
inlet/outlet pair) and fill completely without an air bubble developing inside. 
3. Fill a 3mL syringe with 70% ethanol and connect it to an 18G needle with tygon 
tubing and PE60 tubing assembled together 
4. Connect one of the upper channel inlet/outlet to the ethanol containing 3mL 
syringe and use a syringe pump to flow ethanol through the device at 100uL/min  
1. It is important to let the whole 3mL flow through the device to avoid the 
bleach in the lower channel from coming in contact with the upper 
channel electrodes 
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5. Aspirate out the ethanol with bleach and immerse the chip in ethanol by filling the 
box with 10mL of 70% ethanol. 
6. Bring the device into the tissue culture hood after spraying it down with ethanol, 
and aspirate the ethanol covering the device.  
7. Cover the device in PBS 1X, and using a 200µL pipette SLOWLY INFUSE 200µL 
of PBS through the upper channel. You should see the ethanol leaving the upper 
channel. Do this 3 times.  
8. Aspirate out the the PBS covering device, and replace with an additional 10mL of 
PBS. 
9. Using a 200µL pipette, SLOWLY WITHDRAW 200µL of PBS from the lower 
channel (making sure to withdraw liquid from both inlets/outlets). Repeat this 3 
times and replace the PBS with new 10mL of PBS.  
10. Thread the tubing sets for the device through the holes in the lid for the 
inlets/outlets. 
1. Since there are only 3 tubes and 4 holes, thread two of the tubes through 
the lower channel holes and one of the tubes through the upper channel 
hole. The red circles will indicate which holes to use. 
 
 
Figure A.5. Location of holes in lid for tubing. 
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11. Fill the tubes with PBS using a 3mL syringe, and insert them into the 
corresponding inlet/outlet for the hole the tube was threaded through. 
12. Clamp each of the tubes and check for bubbles. If any bubbles exist then gently 
withdraw PBS through the device to dislodge them. 
13. Aspirate out the PBS ontop of the device, and unclamp the upper channel tube. 
14. Infuse 100µL of fibronectin solution through upper channel inlet/outlet that is not 
connected to the tube. Reclamp the tube and incubate the device at 37ºC for 1 
hour. 
15. Flush out the fibronectin by infusing another 100µL of PBS1X.  
16. Using a 200µL pipette and slowly infusing through the tube-free upper channel 
inlet, displace the PBS in the device with cell growth media. Use the clamps on 
the tubes to direct flow. Thread a lower channel inlet through the top of the 
second box lid that will act as a media reservoir for the lower channel. 
17. Trypsinize the cells in the T25 flask and aspirate out as much media as possible 
before adding 100µL of media. Mix well using a 1000µL pipette set to 100µL. 
18. Making sure to have the lower channel tubes clamped and the upper channel 
tube unclamped, infuse 60µL of cell solution into the tube-free upper channel 
inlet.  
19. Remove the pipette tip first, and then clamp the upper channel tube immediately  
20. Allow the device to incubate for 1 hour at 37ºC. 
21. Add 30mL of media to the top of the device as well as the media reservoir for the 
lower channel. 
22. Having one syringe pump set to Upper and the other set to Lower, withdraw 
media through the device for 24 hours before checking on status of monolayer. 
i. UPPER:  
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1. Ramp up flow rate from 2µL/min to appropriate shear 
stress for cell type 
ii. NOTE: Make sure all of the tubing is prefilled with media – air is a 
compressible fluid and will affect the ability of the syringe pump to 
pull media through the device. 
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This protocol describes the process flow for the synthesis of eHNPs using the 
µVPM platform. The µVPM is a microfluidic tool for mixing precursor solutions together for 
the synthesis of nanoparticles. This device was primarily used for the synthesis of the 
eHNPs we used for the studies presented in this work. 
 
B.2 SYNTHESIS PROTOCOL 
 
Materials: 
1. Harvard Apparatus PhD syringe pump (x2) 
2. µVPM chip  
3. Becton Dickinson (BD) Intramedic polyethylene (PE) tubing, ID0.03in x OD0.048in, 
num. 427416 
4. Cole Parmer Tygon Silicone (CP) tubing, ID0.031in x OD0.093in, num. 95702-00 
5. BD blunt fill needle 18G (1.2mm x 40mm), num 305180 (from VWR) 
6. Plastic BD syringe (need a total of 4 syringes, one of which is 10mL) 
7. Scissors 
8. Calipers 
9. Binder clips (need at least 4) 
10. Synthesis Table (last page of protocol) 
11. Precursors and solvents 
a. For eHNP-A1: apoA1, DMPC lipid, 1X PBS, and 200 proof ethanol. 
12. Collection bottle/tube. 
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1. Set one syringe pump to use a 10 mL syringe running at 1 mL/min (force setting 
should be 100%). 
2. Take out precursor components from the freezer and allow to thaw at room 
temperature.  
3. Insert one BD needle into one end of the CP tubing. 
4. Use the calipers to cut 10 cm sections of CP tubing measured from the tip of the 
needle inside the CP tubing. 
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Figure B.2. Measurement of tubing. 
 
5. On the other end of the 10 cm section of CP tubing holding the BD needle, insert 
~5 mm of PE tubing. 
 
Figure B.3. PE tubing inserted into CP tubing. 
 
6. Cut the PE tubing so that 1cm of the PE tubing is protruding from the CP tubing. 
7. Repeat steps 3-6 to have a total of three 10 cm CP tubing segments. 
8. Make another CP tubing segment with a BD needle and PE tubing segment, but 
cut the CP tubing significantly longer (about 30-40 cm).  
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Figure B.4. Assembled tubing with needles and adapters. 
 
9. Make a luer lock valve using a BD blunt fill needle, a 2 cm segment of CP tubing, 
and a binder clip. 
10. Remove the plunger from a 10 mL syringe, and then plug the luer lock with the 
make shift valve. Fill the syringe with your primary nanoparticle solvent from the 
top (e.g. 1X PBS) and reassemble the syringe, making sure to remove any bubbles. 
11. Connect the three 10 cm tubes with needles to the 3 inlets of the µVPM chip (all 
are on a single side). Note that the PE tube should be inserted into the inlets 
12. Connect the final, longer, tube with needle to the outlet. 
 
 
Figure B.5. Assembled µVPM with tubing. 
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13. Setup the 10 mL syringe in the syringe pump, and attach the syringe to the needle 
of the outlet tubing. 
14. Place the needle ends of the inlet tubing segments into a plastic cup and run the 
syringe pump at 1 mL/min for 10 minutes. 
15. Start preparing precursor solutions from thawed precursor components. For 
eHNP-A1, prepare a 0.2 mg/mL solution of apoA1 in 1X PBS and a 2.75 mg/mL 
solution of DMPC in 200 proof ethanol.  
16. Evenly divide the aqueous precursor between two of the three syringes, and fill the 
remaining syringe with the lipid precursor. Make sure to remove any bubbles from 
the syringes. 
17. Turn off the syringe pump and clamp all 4 tubes with binder clips. 
18. Remove the 10 mL syringe from the pump.  
19. Attach the two aqueous precursor syringes to the two outer inlet needles. Prevent 
any bubbles from forming by creating a liquid interface between the outlet of the 
syringe and the droplet inside the needle. 
20. Attach the lipid precursor syringe to the center inlet needle using the same 
technique as described in the previous step to prevent the formation of bubbles.  
21. Setup the aqueous precursor syringes to one syringe pump, and the lipid precursor 
syringe in the remaining syringe pump. Make sure to have the appropriate settings 
on each pump for the syringe types used (e.g. 3 mL Plastic Syringes). 
22. Set the center syringe pump to infuse at 0.8 mL/min. 
23. Set the outer syringe pump to infuse at 2.2 mL/min. 




Figure B.6. µVPM ready for synthesis. 
 




Figure B.7. Collection of nanoparticles from eHNPs. 
 
26. Remove the clamps and run both syringe pumps.  
27. Collect the resulting nanoparticle solution (avoid collecting the final drops during 
synthesis after the syringe pumps are stopped).  
28. Transfer the nanoparticle solutions to the appropriate centrifugal filter (usually 
10,000 or 30,000 MW filter). Add 10 mL of 1X PBS to the filter and centrifuge at 
3900 RPM for 20 min. Avoid long wait (> 5 min) times between nanoparticle 
collection and centrifugation. 
29. Centrifuge the nanoparticles for a total of 3 times, discarding the filtrate and adding 
more 1X PBS each time. 
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30. Collect the nanoparticles from the centrifugal filter using a 200 µL pipette. Gently 
rinse the filter membranes with the nanoparticle solution before transferring the 
solution to another tube/vial.  





APPENDIX C. RIGHTS AND PERMISSIONS 
Rights and permissions were obtained for the following works for reuse: 
1. Fernandez-Friera, L., et al., Prevalence, Vascular Distribution, and Multiterritorial 
Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA 
(Progression of Early Subclinical Atherosclerosis) Study. Circulation, 2015. 131(24): p. 
2104-13. 
2. Nam, D., et al., Partial carotid ligation is a model of acutely induced disturbed flow, 
leading to rapid endothelial dysfunction and atherosclerosis. American Journal of 
Physiology-Heart and Circulatory Physiology, 2009. 297(4). 
3. Son, D., et al., The atypical mechanosensitive microRNA-712 derived from pre-
ribosomal RNA induces endothelial inflammation and atherosclerosis. Nature 
Communications, 2013. 4. 
4. Karnik, R., et al., Microfluidic Platform for Controlled Synthesis of Polymeric 
Nanoparticles. Nano letters, 2008. 
5. Kim, Y., et al., Mass Production and Size Control of Lipid-Polymer Hybrid 
Nanoparticles through Controlled Microvortices. Nano letters, 2012. 12(7): p. 3587-
3591. 
6. Toth, M.J., T. Kim, and Y. Kim, Robust Manufacturing of Lipid-Polymer Nanoparticles 
Through Feedback Control of Parallelized Swirling Microvortices. Lab Chip, 2017. 
17(16): p. 2805-2813. 
7. Sei, Y.J., et al., Detecting the functional complexities between high-density lipoprotein 
mimetics. Biomaterials, 2018. 170: p. 58-69. 
8. Sei, Y.J., et al., Detection of frequency-dependent endothelial response to oscillatory 
shear stress using a microfluidic transcellular monitor. Sci Rep, 2017. 7(1): p. 10019. 
 114 
REFERENCES 
1. Mozaffarian, D., et al., Executive summary: heart disease and stroke statistics-
2015 update: a report from the american heart association. Circulation, 2015. 
131(4): p. 434-441. 
2. Libby, P., Inflammation and cardiovascular disease mechanisms. The American 
journal of clinical nutrition, 2006. 83(2). 
3. Packard, R.R.S. and P. Libby, Inflammation in Atherosclerosis: From Vascular 
Biology to Biomarker Discovery and Risk Prediction. Clinical Chemistry, 2008. 
54(1): p. 24-38. 
4. Wallez, Y. and P. Huber, Endothelial adherens and tight junctions in vascular 
homeostasis, inflammation and angiogenesis. Biochimica et Biophysica Acta 
(BBA) - Biomembranes, 2008. 1778(3). 
5. Fernandez-Friera, L., et al., Prevalence, Vascular Distribution, and Multiterritorial 
Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA 
(Progression of Early Subclinical Atherosclerosis) Study. Circulation, 2015. 
131(24): p. 2104-13. 
6. Nam, D., et al., Partial carotid ligation is a model of acutely induced disturbed flow, 
leading to rapid endothelial dysfunction and atherosclerosis. American Journal of 
Physiology-Heart and Circulatory Physiology, 2009. 297(4). 
7. Nam, D., et al., A model of disturbed flow-induced atherosclerosis in mouse carotid 
artery by partial ligation and a simple method of RNA isolation from carotid 
endothelium. J Vis Exp, 2010(40). 
8. Son, D., et al., The atypical mechanosensitive microRNA-712 derived from pre-
ribosomal RNA induces endothelial inflammation and atherosclerosis. Nature 
Communications, 2013. 4. 
9. Hofmeister, L.H., et al., Phage-Display-Guided Nanocarrier Targeting to 
Atheroprone Vasculature. ACS nano, 2015. 9(4): p. 4435-4446. 
10. Samady, H., et al., Coronary Artery Wall Shear Stress Is Associated With 
Progression and Transformation of Atherosclerotic Plaque and Arterial 
Remodeling in Patients With Coronary Artery Disease. Circulation, 2011. 124(7): 
p. 779-788. 
 115 
11. Valencia, P.M., et al., Microfluidic Technologies for Accelerating the Clinical 
Translation of Nanoparticles. Nature Nanotechnology, 2012. 7(10): p. 623-629. 
12. Bruckert, E. and D. Rosenbaum, Lowering LDL-cholesterol through diet: potential 
role in the statin era. Current Opinion in Lipidology, 2011. 22(1): p. 43. 
13. Descamps, O.S., et al., Where does the interplay between cholesterol absorption 
and synthesis in the context of statin and/or ezetimibe treatment stand today? 
Atherosclerosis, 2011. 217(2): p. 308-321. 
14. Weber, C. and H. Noels, Atherosclerosis: current pathogenesis and therapeutic 
options. Atherosclerosis: current pathogenesis and therapeutic options, 2011. 
15. Lobatto, M.E., et al., Perspectives and Opportunities for Nanomedicine in the 
Management of Atherosclerosis. Nature Reviews Drug Discovery, 2011. 10(11): p. 
835-852. 
16. Khera, A.V., et al., Cholesterol Efflux Capacity, High-Density Lipoprotein Function, 
and Atherosclerosis. The New England Journal of Medicine, 2011. 364(2): p. 127-
135. 
17. Kontush, A., S. Chantepie, and M.J. Chapman, Small, Dense HDL Particles Exert 
Potent Protection of Atherogenic LDL Against Oxidative Stress. Arterioscler 
Thromb Vasc Biol, 2003. 23(10): p. 1881-8. 
18. Walker, K.H., et al., Cholesterol, Triglycerides, and Associated Lipoproteins. 
Cholesterol, Triglycerides, and Associated Lipoproteins, 1990. 
19. Kontush, A., et al., Structure of HDL: particle subclasses and molecular 
components. Handb Exp Pharmacol, 2015. 224: p. 3-51. 
20. Rosenson, R.S., et al., HDL measures, particle heterogeneity, proposed 
nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem, 
2011. 57(3): p. 392-410. 
21. Besler, C. and T.F. Lüscher, Molecular mechanisms of vascular effects of high‐
density lipoprotein: alterations in cardiovascular disease. EMBO Molecular 
Medicine, 2012. 
 116 
22. Tall, A.R. and L. Yvan-Charvet, Cholesterol, inflammation and innate immunity. 
Cholesterol, inflammation and innate immunity, 2015. 
23. von Eckardstein, A. and D. Kardassis, High Density Lipoproteins. Handbook of 
Experimental Pharmocology. 2015: Springer. 
24. Wang, M. and M.R. Briggs, HDL: the metabolism, function, and therapeutic 
importance. HDL: the metabolism, function, and therapeutic importance, 2004. 
25. Mahmood, S.S., et al., The Framingham Heart Study and the epidemiology of 
cardiovascular disease: a historical perspective. Lancet, 2014. 383(9921): p. 999-
1008. 
26. Kannel, W.B., et al., Risk Factors in Coronary Heart Disease. An Evaluation of 
Several Serum Lipids as Predictors of Coronary Heart Disease; the Framingham 
Study. Ann Intern Med, 1964. 61: p. 888-99. 
27. Tariq, S.M., et al., HDL hypothesis: where do we stand now? Curr Atheroscler Rep, 
2014. 16(4): p. 398. 
28. Lacko, A.G., N.A. Sabnis, and B. Nagarajan, HDL As a Drug and Nucleic Acid 
Delivery Vehicle. HDL as a drug and nucleic acid delivery vehicle, 2015. 
29. Subramanian, C., et al., Synthetic high-density lipoprotein nanoparticles: A novel 
therapeutic strategy for adrenocortical carcinomas. Surgery, 2015. 
30. McMahon, K. and C. Thaxton, High-density lipoproteins for the systemic delivery 
of short interfering RNA. Expert Opinion on Drug Delivery, 2013: p. 117. 
31. McMahon, K.M., et al., Biomimetic High Density Lipoprotein Nanoparticles for 
Nucleic Acid Delivery. Nano letters, 2011. 11(3): p. 1208-1214. 
32. Barter, P.J., et al., Antiinflammatory Properties of HDL. Circulation Research, 2004. 
95(8): p. 764-772. 
33. Kratzer, A., H. Giral, and U. Landmesser, High-Density Lipoproteins As Modulators 
of Endothelial Cell Functions: Alterations In Patients with Coronary Artery Disease. 
Cardiovascular Research, 2014. 103(3): p. 350-361. 
 117 
34. Kontush, A., M. Lhomme, and M.J. Chapman, Unraveling the complexities of the 
HDL lipidome. J Lipid Res, 2013. 54(11): p. 2950-63. 
35. Eren, E., N. Yilmaz, and O. Aydin, Functionally Defective High-Density Lipoprotein 
and Paraoxonase: A Couple for Endothelial Dysfunction in Atherosclerosis. 
Cholesterol, 2013. 2013: p. 792090. 
36. Vandenbroucke, E., et al., Regulation of endothelial junctional permeability. Annals 
of the New York Academy of Sciences, 2008. 1123: p. 134-145. 
37. Shah, A.S., et al., Proteomic diversity of high density lipoproteins: our emerging 
understanding of its importance in lipid transport and beyond. J Lipid Res, 2013. 
54(10): p. 2575-85. 
38. Navab, M., G.M. Anantharamaiah, and S.T. Reddy, Apolipoprotein AI Mimetic 
Peptides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005. 
39. Navab, M., et al., Peptide Mimetics of Apolipoproteins Improve HDL Function. J 
Clin Lipidol, 2007. 1(2): p. 142-7. 
40. Kingwell, B.A., et al., HDL-Targeted Therapies: Progress, Failures and Future. 
Nature Reviews Drug Discovery, 2014. 13(6): p. 445-464. 
41. Andrews, J., et al., Effect of serial infusions of reconstituted high-density lipoprotein 
(CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. 
Cardiovasc Diagn Ther, 2017. 7(1): p. 45-51. 
42. Lincoff, A.M., et al., Evacetrapib and Cardiovascular Outcomes in High-Risk 
Vascular Disease. N Engl J Med, 2017. 376(20): p. 1933-1942. 
43. Rader, D.J. and A. Daugherty, Translating molecular discoveries into new 
therapies for atherosclerosis. Nature, 2008. 451(7181): p. 904-13. 
44. Gu, F., et al., Precise engineering of targeted nanoparticles by using self-
assembled biointegrated block copolymers. Proceedings of the National Academy 
of Sciences, 2008. 
45. Soppimath, K.S., et al., Biodegradable polymeric nanoparticles as drug delivery 
devices. Journal of Controlled Release, 2001. 
 118 
46. Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. 
Nature Reviews Drug Discovery, 2005. 4(2): p. 145-160. 
47. Kim, B.Y., J.T. Rutka, and W.C. Chan, Nanomedicine. The New England journal 
of medicine, 2010. 363(25): p. 2434-2443. 
48. Cormode, D.P., et al., Nanocrystal core high-density lipoproteins: a multimodality 
contrast agent platform. Nano letters, 2008. 8(11): p. 3715-3723. 
49. Thaxton, C.S., et al., Templated spherical high density lipoprotein nanoparticles. J 
Am Chem Soc, 2009. 131(4): p. 1384-5. 
50. Yang, M., et al., Efficient Cytosolic Delivery of siRNA Using HDL-Mimicking 
Nanoparticles. Small, 2011. 7(5): p. 568-73. 
51. Navab, M., et al., Oral D-4f Causes Formation of Pre-Beta High-Density 
Lipoprotein and Improves High-Density Lipoprotein-Mediated Cholesterol Efflux 
and Reverse Cholesterol Transport from Macrophages in Apolipoprotein E-Null 
Mice. Circulation, 2004. 109(25): p. 3215-20. 
52. Zhang, Z., et al., Biomimetic nanocarrier for direct cytosolic drug delivery. Angew 
Chem Int Ed Engl, 2009. 48(48): p. 9171-5. 
53. Huang, M., et al., GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional 
Nanoplatform for the Combination Therapy of Alzheimer's Disease. ACS Nano, 
2015. 9(11): p. 10801-16. 
54. Kim, Y., et al., Single Step Reconstitution of Multifunctional High-Density 
Lipoprotein-Derived Nanomaterials Using Microfluidics. ACS nano, 2013. 7(11): p. 
9975-9983. 
55. McConathy, W.J., et al., Evaluation of Synthetic/Reconstituted High-Density 
Lipoproteins As Delivery Vehicles for Paclitaxel. Anti-cancer drugs, 2008. 19(2): p. 
183-188. 
56. Sanchez-Gaytan, B.L., et al., HDL-Mimetic PLGA Nanoparticle To Target 
Atherosclerosis Plaque Macrophages. Bioconjugate chemistry, 2015. 
57. Blanco, E., H. Shen, and M. Ferrari, Principles of nanoparticle design for 
overcoming biological barriers to drug delivery. Nat Biotechnol, 2015. 33(9): p. 
941-51. 
 119 
58. Ingber, D.E., Reverse Engineering Human Pathophysiology with Organs-on-Chips. 
Cell, 2016. 164(6): p. 1105-1109. 
59. Kim, Y., et al., Dynamic control of 3D chemical profiles with a single 2D microfluidic 
platform. Lab on a chip, 2011. 11(13): p. 2182-2188. 
60. Karnik, R., et al., Microfluidic Platform for Controlled Synthesis of Polymeric 
Nanoparticles. Nano letters, 2008. 
61. Capretto, L., et al., Micromixing Within Microfluidic Devices. Topics in Current 
Chemistry, 2011. 
62. Ottino, J.M. and S. Wiggins, Applied physics. Designing optimal micromixers. 
Science, 2004. 305(5683): p. 485-6. 
63. Kim, Y., et al., Mass Production and Size Control of Lipid-Polymer Hybrid 
Nanoparticles through Controlled Microvortices. Nano letters, 2012. 12(7): p. 
3587-3591. 
64. Toth, M.J., T. Kim, and Y. Kim, Robust Manufacturing of Lipid-Polymer 
Nanoparticles Through Feedback Control of Parallelized Swirling Microvortices. 
Lab Chip, 2017. 17(16): p. 2805-2813. 
65. Ahn, J., et al., Tumor Microenvironment on a Chip: The Progress and Future 
Perspective. Bioengineering (Basel), 2017. 4(3). 
66. Sei, Y.J., et al., Detecting the functional complexities between high-density 
lipoprotein mimetics. Biomaterials, 2018. 170: p. 58-69. 
67. Huh, D., et al., Reconstituting organ-level lung functions on a chip. Science (New 
York, N.Y.), 2010. 328(5986): p. 1662-1668. 
68. Kim, H.J., et al., Human gut-on-a-chip inhabited by microbial flora that experiences 
intestinal peristalsis-like motions and flow. Lab on a chip, 2012. 12(12): p. 2165-
2174. 
69. Booth, R. and H. Kim, Characterization of a microfluidic in vitro model of the blood-
brain barrier (μBBB). Lab on a Chip, 2012. 12(10): p. 1784-1792. 
 120 
70. Herland, A., et al., Distinct Contributions of Astrocytes and Pericytes to 
Neuroinflammation Identified in a 3D Human Blood-Brain Barrier on a Chip. PLOS 
ONE, 2016. 11(3). 
71. Kim, H. and D.E. Ingber, Gut-on-a-Chip microenvironment induces human 
intestinal cells to undergo villus differentiation. Integrative Biology, 2013. 5(9): p. 
1130-1140. 
72. Torisawa, Y.-s., et al., Bone marrow–on–a–chip replicates hematopoietic niche 
physiology in vitro. Nature Methods, 2014. 11(6): p. 663-669. 
73. Kim, Y., et al., Probing nanoparticle translocation across the permeable 
endothelium in experimental atherosclerosis. Proceedings of the National 
Academy of Sciences of the United States of America, 2014. 111(3): p. 1078-1083. 
74. Ferrell, N., et al., A microfluidic bioreactor with integrated transepithelial electrical 
resistance (TEER) measurement electrodes for evaluation of renal epithelial cells. 
Biotechnology and Bioengineering, 2010. 107(4): p. 707-716. 
75. Odijk, M., et al., Measuring direct current trans-epithelial electrical resistance in 
organ-on-a-chip microsystems. Lab on a Chip, 2014. 15(3): p. 745-752. 
76. Vogel, P.A., S.T. Halpin, and R.S. Martin, Microfluidic transendothelial electrical 
resistance measurement device that enables blood flow and postgrowth 
experiments. Microfluidic transendothelial electrical resistance measurement 
device that enables blood flow and postgrowth experiments, 2011. 
77. Veniant, M., J.P. Clozel, and W. Fischli, A comparison of the effects of renin 
inhibition and angiotensin converting enzyme inhibition upon bradykinin 
potentiation. J Hypertens, 1992. 10(2): p. 155-60. 
78. Pampaloni, F., E.G. Reynaud, and E.H. Stelzer, The third dimension bridges the 
gap between cell culture and live tissue. Nature Reviews Molecular Cell Biology, 
2007. 8: p. 839-845. 
79. Huh, D., G.A. Hamilton, and D.E. Ingber, From 3D cell culture to organs-on-chips. 
Trends Cell Biol, 2011. 21(12): p. 745-54. 
80. El-Ali, J., P.K. Sorger, and K.F. Jensen, Cells on chips. Nature, 2006. 442(7101): 
p. 403-411. 
 121 
81. Moraes, C., et al., Organs-on-a-chip: a focus on compartmentalized microdevices. 
Ann Biomed Eng, 2012. 40(6): p. 1211-27. 
82. Huh, D., et al., Reconstituting organ-level lung functions on a chip. Science, 2010. 
328(5986): p. 1662-8. 
83. Kim, H.J., et al., Human gut-on-a-chip inhabited by microbial flora that experiences 
intestinal peristalsis-like motions and flow. Lab Chip, 2012. 12(12): p. 2165-74. 
84. Zhou, J. and L.E. Niklason, Microfluidic artificial "vessels" for dynamic mechanical 
stimulation of mesenchymal stem cells. Integr Biol (Camb), 2012. 4(12): p. 1487-
97. 
85. Shih, M.C., et al., A microfluidic device mimicking acinar concentration gradients 
across the liver acinus. Biomed Microdevices, 2013. 
86. Suwanpayak, N., et al., Blood cleaner on-chip design for artificial human kidney 
manipulation. Int J Nanomedicine, 2011. 6: p. 957-64. 
87. Kuttenberger, J., E. Polska, and B.M. Schaefer, A novel three-dimensional bone 
chip organ culture. Clin Oral Investig, 2012. 
88. Shein, M., et al., Engineered neuronal circuits shaped and interfaced with carbon 
nanotube microelectrode arrays. Biomed Microdevices, 2009. 11(2): p. 495-501. 
89. Grosberg, A., et al., Muscle on a chip: in vitro contractility assays for smooth and 
striated muscle. Journal of pharmacological and toxicological methods, 2012. 
65(3): p. 126-135. 
90. Ghaemmaghami, A.M., et al., Biomimetic tissues on a chip for drug discovery. 
Drug Discov Today, 2012. 17(3-4): p. 173-81. 
91. Liu, D., et al., Current developments and applications of microfluidic technology 
toward clinical translation of nanomedicines. Adv Drug Deliv Rev, 2018. 128: p. 
54-83. 
92. Friend, J. and L. Yeo, Fabrication of microfluidic devices using 
polydimethylsiloxane. Biomicrofluidics, 2010. 4(2). 
 122 
93. Rohrl, C. and H. Stangl, HDL Endocytosis and Resecretion. Biochim Biophys Acta, 
2013. 1831(11): p. 1626-33. 
94. Lou, B., et al., High-Density Lipoprotein as a Potential Carrier for Delivery of a 
Lipophilic Antitumoral Drug into Hepatoma Cells. World journal of 
gastroenterology : WJG, 2005. 11(7): p. 954-959. 
95. Matz, C.E. and A. Jonas, Micellar Complexes of Human Apolipoprotein A-I with 
Phosphatidylcholines and Cholesterol Prepared from Cholate-Lipid Dispersions. J 
Biol Chem, 1982. 257(8): p. 4535-40. 
96. Shih, A.Y., S.G. Sligar, and K. Schulten, Maturation of High-Density Lipoproteins. 
J R Soc Interface, 2009. 6(39): p. 863-71. 
97. Gu, F., et al., Structures of Discoidal High Density Lipoproteins: A Combined 
Computational-Experimental Approach. J Biol Chem, 2010. 285(7): p. 4652-65. 
98. Thomas, M.J., S. Bhat, and M.G. Sorci-Thomas, Three-Dimensional Models of 
HDL Apoa-I: Implications for its Assembly and Function. J Lipid Res, 2008. 49(9): 
p. 1875-83. 
99. Marrache, S. and S. Dhar, Biodegradable Synthetic High-Density Lipoprotein 
Nanoparticles for Atherosclerosis. Proceedings of the National Academy of 
Sciences of the United States of America, 2013. 110(23): p. 9445-9450. 
100. Leman, L.J., B.E. Maryanoff, and M.R. Ghadiri, Molecules That Mimic 
Apolipoprotein A-I: Potential Agents for Treating Atherosclerosis. J Med Chem, 
2014. 57(6): p. 2169-96. 
101. Qin, S., et al., Reverse D4F, an Apolipoprotein-AI Mimetic Peptide, Inhibits 
Atherosclerosis in Apoe-Null Mice. Journal of cardiovascular pharmacology and 
therapeutics, 2012. 17(3): p. 334-343. 
102. Zhang, Z., et al., HDL-mimicking peptide-lipid nanoparticles with improved tumor 
targeting. Small (Weinheim an der Bergstrasse, Germany), 2010. 6(3): p. 430-437. 
103. Cui, L., et al., A PEGylation-Free Biomimetic Porphyrin Nanoplatform for 
Personalized Cancer Theranostics. ACS Nano, 2015. 9(4): p. 4484-95. 
104. Sei, Y., et al., Engineering Living Systems on Chips: From Cells to Human on 
Chips. Microfluidics and Nanofluidics, 2014. 
 123 
105. Morgan, J.P., et al., Formation of Microvascular Networks In Vitro. Nature 
protocols, 2013. 8(9): p. 1820-1836. 
106. Kim, S., et al., Engineering of functional, perfusable 3D microvascular networks on 
a chip. Lab Chip, 2013. 13(8): p. 1489-500. 
107. Ahn, J., et al., Probing the effect of bioinspired nanomaterials on angiogenic 
sprouting using a microengineered vascular system. IEEE Transactions on 
Nanotechnology, 2017. PP(99): p. 1-1. 
108. Besler, C., T.F. Luscher, and U. Landmesser, Molecular Mechanisms of Vascular 
Effects of High-Density Lipoprotein: Alterations in Cardiovascular Disease. EMBO 
Mol Med, 2012. 4(4): p. 251-68. 
109. Zhang, L., et al., Optimized Negative-Staining Electron Microscopy for Lipoprotein 
Studies. Optimized negative-staining electron microscopy for lipoprotein studies, 
2013. 
110. Gordon, S.M., et al., A comparison of the mouse and human lipoproteome: 
suitability of the mouse model for studies of human lipoproteins. J Proteome Res, 
2015. 14(6): p. 2686-95. 
111. Scarselli, E., et al., The human scavenger receptor class B type I is a novel 
candidate receptor for the hepatitis C virus. EMBO J, 2002. 21(19): p. 5017-25. 
112. Rohrer, L., et al., High-Density Lipoprotein Transport Through Aortic Endothelial 
Cells Involves Scavenger Receptor Bi and Atp-Binding Cassette Transporter G1. 
Circ Res, 2009. 104(10): p. 1142-50. 
113. Xia, P., et al., High Density Lipoproteins (HDL) Interrupt the Sphingosine Kinase 
Signaling Pathway A POSSIBLE MECHANISM FOR PROTECTION AGAINST 
ATHEROSCLEROSIS BY HDL. Journal of Biological Chemistry, 1999. 274(46): p. 
33143-33147. 
114. Clay, M.A., et al., Time sequence of the inhibition of endothelial adhesion molecule 
expression by reconstituted high density lipoproteins. Atherosclerosis, 2001. 
157(1): p. 23-29. 
115. Fotis, L., et al., Intercellular adhesion molecule (ICAM)-1 and vascular cell 
adhesion molecule (VCAM)-1 at the early stages of atherosclerosis in a rat model. 
in vivo, 2012. 26(2): p. 243-250. 
 124 
116. van Haelst, P.L., et al., Acute Myeloid Leukaemia As a Cause of Acute Ischaemic 
Heart Disease. Neth Heart J, 2006. 14(2): p. 62-65. 
117. Denard, B., C. Lee, and J. Ye, Doxorubicin Blocks Proliferation of Cancer Cells 
through Proteolytic Activation of CREB3L1. Elife, 2012. 1: p. e00090. 
118. Sardao, V.A., et al., Morphological Alterations Induced by Doxorubicin on H9c2 
Myoblasts: Nuclear, Mitochondrial, and Cytoskeletal Targets. Cell Biol Toxicol, 
2009. 25(3): p. 227-43. 
119. Nishida, N., et al., Angiogenesis in Cancer. Vasc Health Risk Manag, 2006. 2(3): 
p. 213-9. 
120. Oehler, V.G., et al., The Derivation of Diagnostic Markers of Chronic Myeloid 
Leukemia Progression from Microarray Data. Blood, 2009. 114(15): p. 3292-8. 
121. Van Der Spoel, D., et al., Gromacs: Fast, Flexible, and Free. J Comput Chem, 
2005. 26(16): p. 1701-18. 
122. Marrink, S.J., et al., The Martini Force Field: Coarse Grained Model for 
Biomolecular Simulations. J Phys Chem B, 2007. 111(27): p. 7812-24. 
123. Periole, X., et al., Combining an Elastic Network With a Coarse-Grained Molecular 
Force Field: Structure, Dynamics, and Intermolecular Recognition. J Chem Theory 
Comput, 2009. 5(9): p. 2531-43. 
124. Wassenaar, T.A., et al., Computational Lipidomics with Insane: A Versatile Tool 
for Generating Custom Membranes for Molecular Simulations. J Chem Theory 
Comput, 2015. 11(5): p. 2144-55. 
125. Midtgaard, S.R., et al., Self-Assembling Peptides Form Nanodiscs that Stabilize 
Membrane Proteins. Soft Matter, 2014. 10(5): p. 738-52. 
126. Mishra, V.K., et al., Effect of Leucine to Phenylalanine Substitution on the Nonpolar 
Face of a Class A Amphipathic Helical Peptide on its Interaction with Lipid: High 
Resolution Solution Nmr Studies of 4f-Dimyristoylphosphatidylcholine Discoidal 
Complex. J Biol Chem, 2008. 283(49): p. 34393-402. 
127. Kim, Y., et al., Three-dimensional chemical profile manipulation using two-
dimensional autonomous microfluidic control. J Am Chem Soc, 2010. 132(4): p. 
1339-47. 
 125 
128. Genovese, D., et al., Prevention of self-quenching in fluorescent silica 
nanoparticles by efficient energy transfer. Angew Chem Int Ed Engl, 2013. 52(23): 
p. 5965-8. 
129. Mohan, P. and N. Rapoport, Doxorubicin as a molecular nanotheranostic agent: 
effect of doxorubicin encapsulation in micelles or nanoemulsions on the 
ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm, 2010. 
7(6): p. 1959-73. 
130. Snider, C., et al., MPEx: A Tool for Exploring Membrane Proteins. Protein Sci, 
2009. 18(12): p. 2624-8. 
131. Kim, S., M. Chung, and N.L. Jeon, Three-dimensional biomimetic model to 
reconstitute sprouting lymphangiogenesis in vitro. Biomaterials, 2016. 78: p. 115-
28. 
132. Wang, W., et al., Cationic Polymethacrylate-Modified Liposomes Significantly 
Enhanced Doxorubicin Delivery and Antitumor Activity. Sci Rep, 2017. 7: p. 43036. 
133. Ye, W.L., et al., Cellular uptake and antitumor activity of DOX-hyd-PEG-FA 
nanoparticles. PLoS One, 2014. 9(5): p. e97358. 
134. Kuai, R., et al., High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. 
ACS Nano, 2016. 10(3): p. 3015-41. 
135. Hwang, J.Y., et al., Multimodality imaging in vivo for preclinical assessment of 
tumor-targeted doxorubicin nanoparticles. PLoS One, 2012. 7(4): p. e34463. 
136. Sei, Y.J., et al., Detection of frequency-dependent endothelial response to 
oscillatory shear stress using a microfluidic transcellular monitor. Sci Rep, 2017. 
7(1): p. 10019. 
137. Libby, P., P.M. Ridker, and A. Maseri, Inflammation and atherosclerosis. 
Circulation, 2002. 105(9): p. 1135-43. 
138. Chappell, D.C., et al., Oscillatory shear stress stimulates adhesion molecule 
expression in cultured human endothelium. Circ Res, 1998. 82(5): p. 532-9. 
139. Johnson, B.D., K.J. Mather, and J.P. Wallace, Mechanotransduction of shear in 
the endothelium: Basic studies and clinical implications. Vascular Medicine, 2011. 
16(5): p. 365-377. 
 126 
140. Seebach, J., et al., Endothelial barrier function under laminar fluid shear stress. 
Lab Invest, 2000. 80(12): p. 1819-31. 
141. Ku, D.N., et al., Pulsatile flow and atherosclerosis in the human carotid bifurcation. 
Positive correlation between plaque location and low oscillating shear stress. 
Arteriosclerosis, 1985. 5(3): p. 293-302. 
142. Chatzizisis, Y.S., et al., Role of endothelial shear stress in the natural history of 
coronary atherosclerosis and vascular remodeling: molecular, cellular, and 
vascular behavior. J Am Coll Cardiol, 2007. 49(25): p. 2379-93. 
143. Cunningham, K.S. and A.I. Gotlieb, The role of shear stress in the pathogenesis 
of atherosclerosis. Lab Invest, 2005. 85(1): p. 9-23. 
144. Hwang, J., et al., Oscillatory shear stress stimulates endothelial production of O2- 
from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J 
Biol Chem, 2003. 278(47): p. 47291-8. 
145. Ni, C.W., et al., Development of immortalized mouse aortic endothelial cell lines. 
Vasc Cell, 2014. 6(1): p. 7. 
146. Getz, G.S. and C.A. Reardon, Animal models of atherosclerosis. Arterioscler 
Thromb Vasc Biol, 2012. 32(5): p. 1104-15. 
147. Chiu, J.-J. and S. Chien, Effects of Disturbed Flow on Vascular Endothelium: 
Pathophysiological Basis and Clinical Perspectives. Physiological Reviews, 2011. 
91(1): p. 327-387. 
148. Sorescu, G.P., et al., Bone morphogenic protein 4 produced in endothelial cells by 
oscillatory shear stress stimulates an inflammatory response. J Biol Chem, 2003. 
278(33): p. 31128-35. 
149. Velasco, V., et al., An orbital shear platform for real-time, in vitro endothelium 
characterization. Biotechnol Bioeng, 2016. 113(6): p. 1336-44. 
150. Young, E.W. and C.A. Simmons, Macro- and microscale fluid flow systems for 
endothelial cell biology. Lab Chip, 2010. 10(2): p. 143-60. 
151. VanderLaan, P.A., C.A. Reardon, and G.S. Getz, Site specificity of atherosclerosis: 
site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc 
Biol, 2004. 24(1): p. 12-22. 
 127 
152. Himburg, H.A., S.E. Dowd, and M.H. Friedman, Frequency-dependent response 
of the vascular endothelium to pulsatile shear stress. Am J Physiol Heart Circ 
Physiol, 2007. 293(1): p. H645-53. 
153. Feaver, R.E., B.D. Gelfand, and B.R. Blackman, Human haemodynamic frequency 
harmonics regulate the inflammatory phenotype of vascular endothelial cells. Nat 
Commun, 2013. 4: p. 1525. 
154. Bhatia, S.N. and D.E. Ingber, Microfluidic organs-on-chips. Nature Biotechnology, 
2014. 32(8): p. 760-772. 
155. Hosoya, T., et al., Differential responses of the Nrf2-Keap1 system to laminar and 
oscillatory shear stresses in endothelial cells. J Biol Chem, 2005. 280(29): p. 
27244-50. 
156. Ji, J.Y., H.Y. Jing, and S.L. Diamond, Hemodynamic regulation of inflammation at 
the endothelial-neutrophil interface. Annals of Biomedical Engineering, 2008. 
36(4): p. 586-595. 
157. Jouven, X., et al., Heart-rate profile during exercise as a predictor of sudden death. 
New England Journal of Medicine, 2005. 352(19): p. 1951-1958. 
158. Fox, K., et al., Resting heart rate in cardiovascular disease. J Am Coll Cardiol, 
2007. 50(9): p. 823-30. 
159. Chung, B., et al., Nanomedicines for Endothelial Disorders. Nano Today, 2015. 
10(6): p. 759-776. 
160. Hengzi, W., et al., Optimizing layout of obstacles for enhanced mixing in 
microchannels. Smart Materials and Structures, 2002. 11(5): p. 662-667. 
161. Park, B.Y., R. Zaouk, and M.J. Madou, Fabrication of Microelectrodes Using the 
Lift-Off Technique, in Microfluidic Techniques: Reviews and Protocols, S.D. 
Minteer, Editor. 2006, Humana Press: Totowa, NJ. p. 23-26. 
162. Aran, K., et al., Irreversible, direct bonding of nanoporous polymer membranes to 
PDMS or glass microdevices. Lab Chip, 2010. 10(5): p. 548-52. 
163. Shinwari, M.W., et al., Microfabricated reference electrodes and their biosensing 
applications. Sensors (Basel), 2010. 10(3): p. 1679-715. 
 128 
164. Vickers, K.C., et al., Micrornas Are Transported in Plasma and Delivered to 
Recipient Cells by High-Density Lipoproteins. Nature cell biology, 2011. 13(4): p. 
423-433. 
165. Chen, B., et al., Apolipoprotein AI Tertiary Structures Determine Stability and 
Phospholipid-Binding Activity of Discoidal High-Density Lipoprotein Particles of 
Different Sizes. Protein Sci, 2009. 18(5): p. 921-35. 
166. Frank, P.G. and Y.L. Marcel, Apolipoprotein A-I: Structure-Function Relationships. 
J Lipid Res, 2000. 41(6): p. 853-72. 
167. Fung, K.Y., et al., SR-BI Mediated Transcytosis of HDL in Brain Microvascular 
Endothelial Cells Is Independent of Caveolin, Clathrin, and PDZK1. Front Physiol, 
2017. 8: p. 841. 
168. Pagler, T.A., et al., SR-BI-Mediated High Density Lipoprotein (HDL) Endocytosis 
Leads to HDL Resecretion Facilitating Cholesterol Efflux. J Biol Chem, 2006. 
281(16): p. 11193-204. 
169. Nieland, T.J., et al., Identification of the molecular target of small molecule 
inhibitors of HDL receptor SR-BI activity. Biochemistry, 2008. 47(1): p. 460-72. 
170. Nieland, T.J., et al., Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol 
transport by the small molecules BLT-4 and glyburide. J Lipid Res, 2004. 45(7): p. 
1256-65. 
171. Bertrand, N., et al., Mechanistic understanding of in vivo protein corona formation 
on polymeric nanoparticles and impact on pharmacokinetics. Nat Commun, 2017. 
8(1): p. 777. 
172. Kuai, R., et al., Designer vaccine nanodiscs for personalized cancer 
immunotherapy. Nat Mater, 2017. 16(4): p. 489-496. 
 
